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ABSTRACT 
Gastric cancer worldwide is the fifth most common cancer and has the third highest cancer 
related mortality. Curative treatment includes surgical resection but comes with risk of 
complications and the optimal surgery including extent of lymphadenectomy has evolved over 
time. This thesis aims to assess the impact of surgical treatment and lymphadenectomy in 
gastric cancer and its postoperative short-term outcomes and long-term survival effects. It also 
examines the decision-making process and impact of the variation of different proportion of 
the population that is offered curative treatment for gastric cancer.  
Paper I is a single center retrospective study examining the incidence of postoperative 
pancreatic fistula following gastrectomy with D2 lymphadenectomy and bursectomy. The 
results show that there is an acceptable general complication rate and the risk of postoperative 
pancreatic fistula is low when no concomitant pancreatic resection is carried out. 
Paper II and III are national register-based studies using the National Register of Oesophageal 
and Gastric Cancer (NREV) quality register. The studies examine the impact of different extent 
of lymphadenectomy on postoperative morbidity, mortality and long-term survival. The results 
show that extensive lymphadenectomy, D1+/D2, can be performed with acceptable and low 
postoperative complication rate and mortality and offers a survival advantage compared to 
limited, D0/D1, lymphadenectomy. 
Paper IV is a NREV study examining the different rates of curative gastric cancer resection 
across geographical regions in Sweden and its impact on survival. The results show that the 
rate of resection varies greatly across different regions and years in Sweden indicative of room 
for improvement in the decision-making process. A higher rate of curative resection is 
accompanied with improved survival for the entire population of gastric cancer. 
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1 INTRODUCTION 
1.1 EPIDEMIOLOGY 
Gastric cancer has historically been one of the most common forms of cancer worldwide with 
the second highest disease related mortality 1, 2. However, over the last decades the incidence 
rates have substantially decreased, particularly in Europe and in Northern America 3. The 
incidence is still high in other regions and globally gastric cancer is the fifth most common 
malignancy and accounts for a substantial morbidity and mortality burden and it is the third 
leading cause of cancer mortality 4-6. 
The majority of gastric cancer cases comprises adenocarcinoma as classified in the WHO 
classification from 2010. Infection by Helicobacter pylori (H. Pylori) is regarded as a group 1 
carcinogen by the International Agency for Research on Cancer (IARC). H. Pylori is estimated 
to double the risk of gastric cancer 7, 8 and a high dietary intake of salt is associated with a 
similar risk increase 9, 10. Other risk factors include smoking and male gender 11, 12. Some forms 
are also hereditary and constitutes around 10% of all gastric cancers 13, 14. The incidence rate 
of gastric cancer per 100.000 people in Sweden for 2018 is for male 8.74 and for female 4.64 
15. It has been steadily declining over the last decades and a similar pattern has been observed 
also in other European countries 5. This decrease is believed to be driven by changes in diet 16, 
17 and a lower prevalence of H. Pylori infection. A decrease in the age adjusted incidence of 
gastric cancer has also been observed in the Far East, possibly due to similar changes in the 
exposure to risk factors 5. 
Symptoms of gastric cancer can be diffuse and are often recognized late why many cases are 
advanced at the time of diagnosis, which contributes to the poor prognosis of gastric cancer. A 
review of historical data from three decades up to 1990 showed that only around 35% of 
patients with gastric cancer in non-Japanese series underwent tumour resection, with a curative 
resection rate of only around 18%. Due to several factors, including earlier detection by 
screening, the corresponding resection rate in Japanese series were 93% and 59% respectively. 
Of those undergoing curative resection the mean 5-year survival rate was 39% and 61% for 
non-Japanese and for Japanese series 18. Similar results have also been reported in Korea, where 
a single institution demonstrated an overall 5-year survival rate of 64% for the period 1986-
1990 19. The large difference in survival of patients with gastric cancer between the East and 
West is multi factorial. First, there is a difference in which tumour stage patients are diagnosed, 
with more early gastric cancer in the East, but the prognosis per stage is still superior in the 
East 20, 21. Improvements have been achieved in the treatment of gastric cancer in the past 
decades, but the prognosis is still dire. If there is an actual difference in terms of tumour biology 
in East Asian carcinomas, a difference in tolerability to treatment or better care and treatment 
of gastric cancer in the East is still not clear 22. 
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1.2 DIAGNOSTIC WORK UP 
The diagnosis of gastric cancer is achieved by endoscopy with biopsy and histopathological 
assessment of suspicious macroscopic lesions. Gross classification is divided into categories 
depending on the endoscopic assessment. Superficial tumours are classified according to Paris 
classification and larger tumours are classified according to Borrman 23. The TNM 
classification is according to American Joint Committee on Cancer (AJCC)/Union for 
International Cancer Control (UICC) 8th edition 24. 
The mainstay diagnostic procedures for accurate staging is abdominal/thoracic CT-scan. For 
assessment of tumour depth in early lesions endoscopic ultrasound can be applied 25 and for 
advanced disease staging laparoscopy and peritoneal cytology is used to more accurately 
determine possible peritoneal spread 26. In cases where assessment of distant metastasis is 
inconclusive the use of MRI or FDG-PET-CT may complement the work-up, but no single 
modality has been shown to be superior 27-29. A more stringent investigation protocol has been 
implemented to an increasing extent during the last decade in order to provide an optimal and 
personalized treatment regimen. Regardless of these diagnostic procedures the diagnostic 
accuracy is still only around 60-80% 30 and it has been reported that a change in management 
was made due to too advanced local disease or distant metastases in 8,5-59,6%, as discovered 
during diagnostic laparoscopy 26. The advancements of imaging modalities have most likely 
improved the accuracy of preoperative staging. It has however also made staging assessment 
more complex and difficult to interpret.  
1.2.1 Screening and early detection 
In countries with a high incidence of gastric cancer nationwide screening might have a positive 
effect. There are currently national screening programs in South Korea and Japan. Studies show 
that since the introduction of screening the proportion of early gastric cancers has increased 
and the mortality rate has decreased 19, 31-34. These screening programs might however not yield 
the same effect if introduced in western countries due to differences in incidence rate, 
diagnostic availability and treatment traditions 35. Randomized trials of screening for gastric 
cancer are however lacking. 
1.2.2 Histologic classification 
The term gastric cancer refers to adenocarcinoma of the stomach that is the most common type 
malignancy of the stomach that constitutes around 95 % of all malignant gastric lesions 36. 
Gastric cancer with signet ring cells or linitis plastica, a diffuse gastric cancer with poorly 
differentiated tumour cells characterised by a thick rigid gastric wall, is associated with a worse 
prognosis 37. The Lauren classification of histological subtypes consists of the diffuse 
(undifferentiated) and intestinal type 38. The prognosis for these subtypes is debatable and there 
are studies that imply that prognosis is better for the intestinal type but this difference may not 
necessarily be only related to the histology, but could also be related to more advanced stage 
for the diffuse type compared to the intestinal type 39-42. Less common malignancies in the 
stomach that are not a part of this thesis and therefore not discussed further include 
  INTRODUCTION | 3 
Gastrointestinal Stromal Cell Tumours (GIST), Mucosa Associated Lymphoid Tissue (MALT) 
lymphoma, Neuroendocrine Tumours (NET). 
1.2.3 Molecular classification 
With the improvement of next generation sequencing methods, the understanding and 
knowledge of tumour biology and its importance has progressed 43, 44. The genome for gastric 
cancer and molecular characterization has been published in a trial in 2014 45. This study 
characterized gastric cancer molecular profile in four distinct subgroups. Chromosomal 
instability is the most frequent subgroup with around half of all patients and characterized with 
TP53 mutation. Other groups are those with microsatellite instability (MSI), genomically stable 
group and those with tumours with Epstein-Barr virus infection. 
 
1.3 TREATMENT 
A profound change in the management of cancer patients during the last decade is 
multidisciplinary therapy conferences (MDT). The conference gathers all relevant specialties 
and aims to accurately classify the stage and extent of disease, determine if the disease is 
resectable and along with risk factors asses if the patient is operable. The MDT also aims to 
recommend an individual-based multimodal evidence-based treatment. The ultimate decision 
is however made by the responsible physician together with the patient 46. 
1.3.1 Endoscopic resection 
Early gastric cancer (T1) is defined as tumours confined to the mucosa. If possible, early gastric 
cancer should be resected using endoscopic techniques provided that a radical resection can be 
performed with an adequate margin and with low risk for lymph node metastasis, since this 
does not interfere with the function of the alimentary tract. In a large study of 5265 patients 
with gastric cancer in Japan, 1230 cases had well differentiated intramucosal cancers of a size 
less than 30 mm, none had lymph node metastasis. There were 929 tumours without ulceration 
regardless of tumour size, and those were also without lymph node metastasis 47. This is 
corroborated by another study from Japan examining 1196 patients with early gastric cancer 
with an overall lymph node metastatic rate of only 3,5% 48. In multivariate analysis, lymphatic 
vessel invasion, histologic ulceration and tumour size of more than 30 mm were independent 
risk factors of lymph node metastasis and the prevalence of lymph node metastasis in cases 
without these independent risk factors was only 0,36%. Based on these and similar studies, the 
Japanese Gastric Cancer Association guidelines for endoscopic treatment of early gastric 
cancer criteria consist of: absolute indication: differentiated adenocarcinoma with a depth of 
cT1a and without ulceration (with ulceration up to 3 cm in tumour diameter) and expanded 
indication: un-differentiated adenocarcinoma without ulcerative findings, depth of cT1a and 
diameter < 2 cm49. After endoscopic resection a careful histopathological assessment of the 
specimen to determine the exact tumour size, the depth of growth, radicality and 
lymphovascular invasion is essential for the following decision if complementary surgery with 
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lymphadenectomy is indicated or if the endoscopic treatment is to be regarded as curative. The 
5-year survival rate after applying this strategy of organ preserving treatment for early gastric 
cancer is as high as 83% to 97.5% 50-52. 
1.3.2 Surgical resection 
In cases where organ preserving endoscopic treatment is not possible, surgical resection is 
standard of care in the treatment of gastric cancer. The two most common types of resections 
are total gastrectomy involving removal of the entire stomach and distal gastrectomy which 
involves removal of the distal part of the stomach including the pylorus. The decision on what 
extent of the stomach that needs to be removed is dependent on tumour location, size and the 
histopathological characteristics since the diffuse type cancer has a more infiltrative growth 
pattern where more extensive surgery may be mandated. A French prospective controlled study 
53, performed before neoadjuvant/adjuvant oncological treatment became standard of care, 
comparing total versus subtotal gastrectomy for cancer in the gastric antrum showed no 
difference in postoperative mortality 1,3% and 3,2 % respectively and an equal 5-year survival 
rate, 48% in both groups. Reconstruction of the alimentary tract after gastrectomy can be 
performed in many ways. For total gastrectomy Roux en-Y oesophagojejunostomy and 
jejunojejunostomy is the standard and most prevalent reconstruction method 54. An alternative 
reconstruction consists of functional jejunal interposition (Henley´s reconstruction) and there 
is low grade evidence suggesting an improved functional outcome, but this procedure is 
performed very seldom due to the increased complexity 55. For distal gastrectomy, 
reconstruction can be performed with Billroth 1 gastroduodenostomy, Billroth 2 with omega 
loop gastrojejunostomy with or without Braun jejunojejunostomy or Roux-en-Y 
gastrojejunostomy with jejunojejunostomy. With the evolution of gastric surgery from ulcer 
surgery to cancer surgery, there has been a shift towards reconstruction with a Roux-en-Y limb 
following distal gastrectomy, however there are no clear evidence to which is superior in terms 
of postoperative complications and long term quality of life 56-59. In the scarcer proximal 
gastrectomy, reconstruction is typically performed with a jejunal pouch interposition. In 
superficial, small and well defined centrally located tumours a pylorus preserving central 
gastrectomy has been shown to give a better functional outcome, probably because of the 
preserved duodenal passage of nutrients. These less common methods of reconstruction seem 
to have a better functional outcome compared to standard gastrectomy according to some trials 
60-62. 
1.3.2.1 Lymphadenectomy 
The extent of lymphadenectomy in gastric cancer surgery has been developed over several 
decades and studied extensively 63. The lymph node stations in the upper abdomen have been 
assigned numbers which are based on the lymphatic flow at different tumour sites of the 
stomach and the associated long-term survival depending on the presence of metastasis in each 
specific lymph node station. The stations most adjacent to the stomach are called the gastric 
lymph nodes and numbered 1-6. The stations around the celiac artery and branches of the artery 
and splenic hilum are numbered 7-11. The lymph node station in the hepatoduodenal ligament 
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is numbered 12 and is subdivided according to proximity to the artery, bile duct or portal vein. 
Stations around the superior mesenteric vessels and the middle colic branch are numbered 14a, 
14v and 15. The peripancreatic lymph node stations are numbered 13 and 17-18. Para-aortic 
stations are numbered 16. Stations around the diaphragm are numbered 19-20. The associated 
lymph nodes in the lower thorax associated to gastric cancer surgery and lymphadenectomy 
are numbered 110-112. 
Originally the lymph node stations were grouped together into tiers depending on the tumour 
location. This system corresponded to similar frequency and pattern of metastasis in each 
lymph node station for the respective tier depending on the location of the primary tumour 20, 
64, 65. This nomenclature generated three tiers of lymph node groups and thus three 
corresponding extents of lymphadenectomy, assigned D1 involving dissection of tier 1 nodes, 
D2 involving tier 1 and 2 nodes, D3 tier 1, 2 and 3 nodes and D0, lymphadenectomy not 
sufficient for D1, D2 or D3. This system was not entirely adopted in the West because of its 
complexity and difficult to understand since the lymph node stations included in each tier 
differed depending on the location of the tumour and not on the type of gastrectomy that was 
performed. This grouping of tiers has been simplified and reclassified in the 3rd English edition 
of Japanese gastric cancer treatment guidelines 66. The lymphadenectomy extents are now 
classified as D0, D1, D1+ and D2 and the respective stations required for adequate 
lymphadenectomy for each extent is specified depending on what type of surgical procedure 
rather than tumour location. The lymphadenectomy that should be performed is specified for 
total gastrectomy, distal gastrectomy, pylorus-preserving gastrectomy and proximal 
gastrectomy now according to the 5th English version of Japanese gastric cancer treatment 
guidelines 49 (Figure 1). 
 
 
Figure 1. Extent of lymphadenectomy for total and distal gastrectomy. Number refer to lymphnode stations as 
specified above and complete dissection of blue nodes are necessary for D1 lymphadenectomy, addition of orange 
nodes for D1+ lymphadenectomy and addition of red nodes for D2 lymphadenectomy. Reprinted with permission 
from the publisher. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer (2020). 
https://doi.org/10.1007/s10120-020-01042-y. 
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Early non-randomized studies regarding the oncological outcome depending on extent of 
lymphadenectomy in Japan show that more extensive lymphadenectomy resulted in improved 
long-term survival and acceptable morbidity 20, 67, 68. Based on this experience, D2 gastrectomy 
became standard of care in Japan for advanced gastric cancer already in the 1980’s. Early small 
non-Japanese trials found conflicting results regarding lymphadenectomy extent showing no 
favour for extensive lymphadenectomy and some showing a slight possible advantage but not 
definitive results 69-71. 
In the 1990’s two large European randomized controlled trials were conducted comparing D1 
versus D2. The initial reports of short-term data showed a substantial increased amount of 
postoperative complications, morbidity and mortality 72, 73. The analysis of those data attributed 
the high complication rate to a high rate of concomitant pancreatic tail resection and 
splenectomy as an integral part of D2 dissection. Long-term follow-up therefore failed to show 
any benefit for D2 dissection 74, 75 and the initial conclusions did not favour D2 dissection. 
However, the 15-year follow up 76 has shown a survival benefit of D2 after exclusion of 
postoperative mortalities. The overall conclusions from these trials were that the high 
postoperative morbidity and mortality cancelled the proposed oncological benefit of D2 
dissection. Other concerns from these studies were that pancreatic tail resection and 
splenectomy as an integral part of D2 was attributed in the high complication rate and during 
the 2000’s these procedures have only been performed in locally advanced tumours or in cases 
with signs of lymph node metastases in the splenic hilum. A majority of the surgery in the 
European studies were performed in low volume centers, raising questions about the quality of 
surgery. This aspect has certainly changed over the last decade with the implementation of 
centralization of surgery. 
Due to the implementation of D2 gastrectomy as a standard procedure another European 
randomized controlled trial 77 was conducted between 1998 and 2006. This study showed 
substantially lower rates of postoperative morbidity in D2 vs D1 and no differences in mortality 
compared to the two previous European trials 78, but still no difference in overall 5-year survival 
between D1 and D277. It was suggested that the failure to show a benefit of D2 occurred due to 
“contamination”, which means that the D1 group underwent more lymphadenectomy than 
should have been done, as well as a high share of T1 cancers that probably did not benefit from 
D2. It was also concluded that D2 lymphadenectomy might be of benefit in a subgroup of 
patients with more advanced T2-T4 and N+ disease. 
A single center randomized controlled trial that earlier had been performed in Taiwan 
comparing D1 to D3 (in principle very similar to D2) 79, 80 showed a survival benefit for D3 
and low complication rates. The possible value of an even more extensive lymphadenectomy 
was evaluated in a large study from Japan comparing D2 gastrectomy with or without para-
aortal lymphadenectomy. The data showed an increase in postoperative morbidity without any 
improvement in long term survival after para-aortal lymphadenectomy 81. 
It can be argued that there is still no large scale European RCT showing a survival benefit for 
D2 versus D1. The previous Japanese non RCT studies show good results for D2 and the 
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current results of D2 surgery in clinical practice in Far East are far superior compared to 
European centers, making an RCT in the Far East comparing D1 vs D2 impossible to conduct 
due to ethical considerations. A recent meta-analysis 82 however concludes that there are still 
questions regarding lymphadenectomy extent that should be answered through a randomized 
clinical trial and another large scale multicenter RCT was recommended. It should be noted 
that all studies of D1 vs. D2, both RCTs and cohort studies were performed before the 
introduction of neoadjuvant and or adjuvant treatment as standard of care. Therefore, there is 
limited data in the literature showing benefit of D2 in patients that also receive oncological 
therapy. 
1.3.2.2 Bursectomy 
Bursectomy in gastric cancer involves the removal of the peritoneal leaf comprising the lesser 
sac. In Japan, previously it has been routinely performed for tumours invading the serosa but 
avoided in early T1/T2 tumours 66. A randomized clinical trial from Japan 83 comparing 
bursectomy vs non bursectomy in patients with T2 or T3 tumours showed similar morbidity 
and mortality rates and concluded that bursectomy could be performed safely by experienced 
surgeons. Long term follow-up of that study 84 show that 5-year overall survival was 77,5% for 
the bursectomy group and 71,3% for the non-bursectomy group. The difference was not 
significant, but trial design was set up for noninferiority of the omission of bursectomy and 
they conclude that bursectomy should not be regarded as a completely redundant procedure. A 
meta-analysis 85 of both RCT and non RCT show no overall survival benefit for bursectomy 
versus non-bursectomy. In subgroup analysis of serosa-positive patients, bursectomy might 
improve survival but the difference was not statistically significant. In a recent RCT of 1204 
patients, half were randomized to bursectomy and the other half to non-bursectomy. The results 
did not reveal any survival advantage for bursectomy. The bursectomy group however had 
more incidence of postoperative pancreatic fistula. Conclusions from this trial recommend that 
bursectomy should not be performed as standard surgery for patients with cT3/T4a resectable 
gastric cancer 86. 
1.3.2.3 Laparoscopic surgery 
Laparoscopic gastrectomy has been introduced to an increasing degree during the last years. 
There is no clear indication for when laparoscopic gastrectomy may be applied. In the Far East 
T1b-T2 N0-1 has been the most common indication. There are numerous case series and cohort 
studies of laparoscopic gastrectomy, but randomized trials comparing this approach vs open 
gastrectomy are less common. In an early randomized controlled trial comparing laparoscopic 
versus open subtotal gastrectomy for distal cancer performed between 1992-1996 showed no 
significant difference in postoperative mortality which was in the range of 3,3% to 6,7 %, 
postoperative morbidity was 27% for both groups,  or 5-year overall survival that was around 
55% for both groups 87. A randomized study performed between 2008 and 2009 comparing 
laparoscopy-assisted gastrectomy versus open gastrectomy in clinical T2-T3 cancer showed a 
3-year overall survival of 67% and 54%, no significant difference, for the laparoscopic and 
open approach respectively 88. Similarly, a study comparing early distal T1 tumours that were 
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resected with laparoscopy-assisted or open distal gastrectomy showed similar 5-year overall 
survival of 97,6% and 96,3% respectively with no significant differences in postoperative 
complications 89. The increasing amount of evidence for laparoscopic surgery in gastric cancer 
show that laparoscopic gastrectomy in non-advanced gastric cancer cases is non-inferior to 
open surgery regarding overall survival in the hands of experienced surgeons. In terms of 
postoperative complications there might be slight advantages for laparoscopic surgery 90. Most 
studies are however conducted in Korea and Japan and are single center trials. There are two 
recently published large scale multicenter randomized controlled trials investigating long term 
survival after laparoscopic and open distal gastrectomy for clinical stage I disease. The results 
show that laparoscopic distal gastrectomy seems to be non-inferior to open surgery in regard 
to overall survival and diseases free survival 91, 92. 
 
1.3.2.4 Multivisceral resection 
Curative intended treatment for gastric cancer consists of resection of the tumour with radical 
margins and a microscopically radical (R0) resection is a positive prognostic factor for survival 
93, 94. In cases with locally advanced cancer with suspected or confirmed growth into adjacent 
organs a question is raised regarding resectability. A systematic review of multivisceral 
resection show perioperative mortality ranging from 1,9% to 15% and a 5-year survival of 0% 
to 40%. The rate of successful R0 resection following multivisceral resection was 38%-100% 
in the studies examined. The authors conclude that the postoperative morbidity and mortality 
might be higher after multivisceral resection but the potential benefit of achieving radical 
resection should outweigh the increased perioperative risks. Adequate identification of suitable 
patients that will benefit from this extensive procedure is essential 95, 96. 
1.3.2.5 HIPEC and metastatic surgery 
Around 5-20 % of patients with gastric cancer planned for curative resection are found to have 
peritoneal dissemination during laparotomy 97, 98. The results of peritonectomy and 
hyperthermic intraperitoneal chemotherapy (HIPEC) in selected cases of other neoplastic 
abdominal malignancies than gastric cancer, in particular pseudomyxoma and colorectal 
cancer, have been encouraging 99, 100 but the few studies 101, 102 on peritonectomy and HIPEC 
or early postoperative intraperitoneal chemotherapy (EPIC) in advanced gastric cancer with 
peritoneal carcinomatosis has shown high morbidity rates. In certain subgroups of gastric 
cancer patients that are treated with peritonectomy and HIPEC, where macroscopic radicality 
can be achieved, the initial results may be promising 102, but the long-term results are very 
uncertain. A Spanish multicenter retrospective trial showed that in selected patients, especially 
with peritoneal carcinomatosis index less than 7, cytoreductive surgery (CRS) and HIPEC 
could be of benefit but conclusions from that trial still warrant more studies 103. There is one 
published randomized clinical trial from China studying CRS alone versus CRS and HIPEC 
that showed a median survival of 6.5 months and 11 months respectively 104. Sample size was 
only 68 patients and no widespread general conclusions can be drawn. There is an ongoing 
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French randomized multicenter study investigating the role of perioperative HIPEC without 
CRS in patients with high risk gastric cancer but with no macroscopic peritoneal 
carcinomatosis 105and a German randomized study comparing the effect of CRS with or 
without HIPEC for peritoneal carcinomatosis (NCT02158988). In a few years more 
information and data will be available regarding the treatment of peritoneal carcinomatosis and 
the role of CRS and HIPEC but presently it is not recommended outside clinical trials. 
There is a current randomized trial comparing the effect of surgery in gastric cancer patients 
with limited metastatic disease where resection is possible. The trial compares chemotherapy 
alone versus chemotherapy plus surgical resection and results are highly anticipated106. 
Series of carefully selected patients with liver metastases from gastric cancer have shown a 5-
year survival of up to 30% after multimodal treatment including liver resection 107-109. Given 
the very limited experience, curatively intended treatment for gastric cancer liver metastases is 
regarded as treatment that should not be performed outside clinical trials. 
1.3.2.6 Sentinel node navigation surgery 
Sentinel node surgery for early gastric cancer has been attempted and there are ongoing trials 
investigating this further. Although for gastric cancer the concept of sentinel node surgery has 
not come as far as for breast cancer the results are promising. A multicenter trial of sentinel 
node surgery for early gastric cancer 110 with dual tracer technique show a sentinel node 
detection rate of 97.5% and an accuracy of 99% to evaluate nodal metastasis. There were 
however four (1%) false negative sentinel node biopsies. A large multicenter phase III trial is 
currently ongoing studying sentinel basin dissection with stomach preserving surgery versus 
standard D1+ lymphadenectomy for early gastric cancer 111. A quality control study from the 
RCT examining safety of the procedure show that laparoscopic sentinel basin dissection can 
be performed safely. There were only eight postoperative complications out of 108 patients and 
only one patient with Clavien-Dindo grade IIIa 112. The trial might come with promising results. 
However, the patients included are early gastric cancers with cT1N0M0 and the proportion of 
patients in western population with clinical early gastric cancer at presentation is much less 
than in Japan and South Korea. The possible implementation of this in Sweden must be done 
with caution and more trials are needed. 
 
1.3.3 Postoperative complications 
Surgery for gastric cancer encompasses a vast variety of complications that may arise, and 
surgery is often carried out in frail and elderly patients with comorbidities. Complication rates 
and the severity of these vary substantially in the literature and depend on how complications 
are defined, patient selection and the extent of surgery. A single center retrospective study of 
D2 gastrectomy in Sweden 113 showed that the total complication rate of Clavien 3b or higher 
amounts to around 24 %. When compared to the previous large European randomized trials the 
postoperative morbidity and complication rate where lower in the Italian D2 trial 78 with 18% 
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overall morbidity rate in the D2 group. This is a substantial difference when compared to the 
British MRC and Dutch trial 72, 73 with overall morbidity of 43-46% in the D2 group and a 
mortality of 10-13%. This evolution and improvement of complication rate should be expected 
as many different components in the management of gastric cancer has improved over the years 
and the Italian D2 trial was conducted nearly a decade later than the two former. The key factor 
for reducing the postoperative complication is probably the omission of routine 
pancreaticosplenectomy as part of D2. Centralization and increasing hospital volume has most 
likely also reduced complication rate as the Taiwanese single center trial with high volume 
shows no postoperative mortality and a complication rate of merely 17% in the D3 group 80. 
Another key step in reducing postoperative complications, shown mostly after colorectal 
surgery, has been the implementation of enhanced recovery programs (ERP) 114, 115. There is a 
consensus guideline for ERP gastric cancer program 116. An Italian study has evaluated the 
implementation of the program at several institutions showing a wide range of adherence to the 
program and that further improvements can be made 117. 
1.3.3.1 Postgastrectomy syndromes 
Dumping is a common syndrome after gastrectomy which can include symptoms such as 
abdominal pain, diarrhea, nausea, bloating as well as palpitations, flush, tachycardia and 
diaphoresis. It can occur early within 30 minutes from meal intake or late, a few hours after 
meal. Symptoms can be alleviated with dietary modifications. 
There are also numerous nutritional deficiencies that can occur after gastric cancer surgery. 
Among the more common are vitamin B12 that occur due to loss of Intrinsic Factor. Iron 
deficiency as well as Vitamin D and calcium deficiency can also occur and depends somewhat 
on extent of resection and reconstruction methods after gastrectomy 118. 
 
1.3.4 Oncological therapy 
1.3.4.1 Perioperative therapy 
The introduction of chemotherapy and/or radiotherapy has changed the general treatment 
paradigm for gastric cancer. There are basically three principally different treatments that are 
practiced in the United States, Europe and Far East respectively, based on three different pivotal 
clinical trials. A trial performed in the USA 119 on patients with adenocarcinoma of the stomach 
or gastroesophageal junction found an increase in median overall survival from 27 months to 
36 months in patients who had adjuvant chemoradiotherapy compared to surgery alone. The 
treatment arm consisted of postoperative fluorouracil and leucovorin and a total of 45 Gy 
administered at 1.8 Gy for 25 days. Around 64% of patients could receive the treatment as 
planned. 
A British trial that included both gastric cancer and cancer of the gastroesophageal junction 120 
showed a survival benefit of 13% for neoadjuvant and adjuvant chemotherapy (perioperative) 
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consisting of epirubicin, cisplatin and 5-fluorouracil. Treatment consisted of 3 preoperative and 
3 postoperative cycles. Each cycle lasting for 3 weeks with epirubicin and cisplatin infusion at 
first day of cycle and 5-fluorouracil infusion daily for 21 days. Postoperative morbidity rates 
were similar in both treatment arms but only around 40 percent of the assigned patients could 
receive all cycles of perioperative chemotherapy. 
A Japanese trial comparing adjuvant S-1 (a combination of an oral prodrug to fluorouracil, an 
inhibitor of fluorouracil degradation, and an inhibitor of fluorouracil phosphorylation to reduce 
the gastrointestinal toxicity) to surgery showed a 3-year survival rate of 80,1% with S-1 
compared to 70,1% in patients that had D2 gastrectomy 121. The treatment arm received daily 
oral S1 for four weeks in a six-week cycle, and treatment continued for 1 year after surgery. In 
total around 66% received treatment for 1 year after surgery. However, amongst these patients, 
dosage had to be decreased for roughly half of the patients. These three trials have had a major 
impact on treatment guidelines in the regions where the trials were performed. 
 
Another subsequent multicenter trial in China, South-Korea and Taiwan studied adjuvant 
treatment following surgery compared to surgery alone. The treatment consisted of 
capecitabine and oxaliplatin for two weeks in a three-week cycle for six months. The estimated 
overall 5-year survival was 78% and 69% for adjuvant chemotherapy and surgery alone 
respectively 122. The ARTIST trial 123 compared adjuvant chemotherapy with capecitabine and 
cisplatin to adjuvant chemoradiotherapy with capecitabine and cisplatin and a total radiation of 
45 Gy fractionated to 1.8 Gy 5 days a week for 5 weeks. Long term results show similar disease-
free survival and overall survival for both treatment arms, but a subgroup analysis show that 
chemoradiotherapy improved disease-free survival in patients with N+ disease and intestinal 
type cancer. The recent CRITICS trial 124 comparing perioperative chemotherapy versus 
perioperative chemotherapy with the addition of radiotherapy in the postoperative phase did 
not show any survival benefit with the addition of radiotherapy. Results from a French trial 125 
comparing perioperative chemotherapy with cisplatin and fluorouracil to surgery alone show 
an overall survival advantage in favour for the perioperative chemotherapy group with a 5-year 
survival of 38% and 24% for the surgery alone group. A recent published randomized trial 
comparing standard ECF/ECX perioperative treatment compared to perioperative 5-
Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) showed an increased median overall 
survival from 35 months to 50 months126. The treatment arm was administered for four 
preoperative and four postoperative cycles and each cycle lasted for 2 weeks as compared to 
the control arm which consisted of three preoperative and postoperative cycles. A total of 46% 
of patients completed all cycles in the treatment arm (FLOT) and only 37% completed all 
cycles in the control arm. A pathological complete response was achieved in 16% of cases in 
the treatment arm as compared to 6% in the control arm 127. 
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These trials of perioperative and adjuvant oncological therapy have shown a benefit of 
oncological therapy in addition to surgery. However, it has been discussed if chemotherapy 
adds any oncological advantage or if it merely complements inadequate lymphadenectomy, in 
particular because the dominant lymphadenectomy extent in the US trial was D0 128, 129. These 
new insights examined further in more ongoing trials but the trial settings for these large RCT 
still do not necessarily reflect clinical reality. Real life data on neoadjuvant and adjuvant 
therapy in gastric cancer are however scarce. A recent Norwegian population-based study 
comparing no perioperative oncological therapy in one time period to another with 
perioperative chemotherapy showed no benefit for chemotherapy 130. However, this study was 
hampered by a low adherence, since only 44% of the patients tolerated the full treatment 
regimen, thus questioning to what extent the results from clinical trials translate into similar 
results in real life. A table summarizing selected studies on oncological therapy can be seen in 
Table 1. 
1.3.4.2 Antibody therapy/Immunotherapy 
There is an ongoing RCT studying the effect of addition of Trastuzumab or Trastuzumab and 
Pertuzumab to perioperative chemotherapy in HER2 positive gastric cancer patients 131. The 
recently published preliminary results of the MAGIC-b trial investigating the effect of 
bevacizumab in addition to perioperative chemotherapy showed no evidence of benefit for the 
use of bevacizumab. This trial however also includes adenocarcinoma of the lower oesophagus 
and not strictly gastric cancer 132. 
Immunotherapy has gained strong positive evidence in the treatment of melanoma and renal 
cell carcinoma but for gastric cancer there is still no shown advantages. There are multiple 
studies showing the prognostic importance of PD-L1, PD1/PD-L2 and MSI status as 
summarized in a recent review 133. But interventional trials are not yet up to speed. A phase III 
trial conducted in Japan, South-Korea and Taiwan included 493 patients with advanced gastric 
cancer that were refractory or intolerable to two previous chemotherapy regimens and 
randomly assigned them to nivolumab or placebo in a 2:1 fashion. The results show a 
significantly improved median overall survival for nivolumab group, but the efficacy was 
modest as the survival improved from 4.14 months to 5.26 months in the nivolumab group 134. 
The results at this moment has little clinical implementation importance in western patients but 
might be the start of a future new therapeutic adjunct in the treatment of gastric cancer. 
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Table 1. Selected studies on oncological therapy in curative treatment of gastric cancer. 
Study Patients Treatment arms Results 
Macdonald, NEJM 
2001 119 
556 patients with gastric 
cancer or GEJ cancer 
Surgery alone vs 
Adjuvant 5-Fu + 
Leucovorin + 45 Gy 
radiotherapy 
Median survival 27 vs 36 
months. HR 1.35 (95% 
CI 1.09-1.66) p = 0.005 
Cunningham, 
NEJM 2006 120 
503 patients with gastric 
cancer, GEJ cancer or cancer 
to lower oesophagus. 
Perioperative ECF vs 
surgery alone 
5-year OS 36% vs 23 %. 
HR 0.75 (95% CI 0.60-
0.93) p = 0.009 
Sakuramoto, 
NEJM 2007 121 
1059 patients with gastric 
cancer 
Adjuvant S-1 vs surgery 
alone 
3-year OS 80.1% vs 
70.1%. HR 0.68 (95% CI 
0.52-0.87) p = 0.003 
Ychou, JCO 2011 
125 
224 patients with gastric 
cancer, GEJ cancer or cancer 
to lower oesophagus 
Perioperative 5-FU and 
cisplatin vs surgery alone 
5-year OS 38% vs 24%. 
HR 0.69 (95% CI 0.50-
0.95) p = 0.02 
Noh, Lancet 
oncology 2014 122 
1035 patients with gastric 
cancer 
Adjuvant oxaliplatin and 
capecitabine vs surgery 
alone 
5-year OS 78% vs 69%. 
HR 0.66 (95% CI 0.51-
0.85) p = 0.0015 
Park, JCO 2015 123 458 patients with gastric 
cancer 
Adjuvant cisplatin and 
capecitabine vs Adjuvant 
cisplatin, capecitabine 
and 45 Gy radiotherapy 
5-year OS 73% vs 75%. 
HR 1.13 (95% CI 0.78-
1.65) p = 0.527 
Cats, Lancet 
oncology 2018 124 
788 patients with gastric 
cancer or GEJ cancer 
Perioperative ECX/EOX 
vs preop ECX/EOX and 
postop CX and 45 Gy 
radiotherapy 
5-year OS 42% vs 40%. 
HR 1.01 (95% CI 0.84-
1.22) p = 0.90 
Al-Batran, Lancet 
2019 126 
716 patients with gastric 
cancer or GEJ cancer 
Perioperative FLOT vs 
perioperative ECF/ECX 
5-year OS 45% vs 36% 
HR 0.77 (95% CI 0.63-
0.94) p = 0.012 
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1.3.5 Palliative therapy 
1.3.5.1 Palliative surgery 
For patients with specific tumour related symptoms surgery can be an option. In patients with 
gastric outlet obstruction (GOO) both duodenal stenting and by-pass with gastrojejunostomy 
are possible alternatives. A systematic review comparing the two methods show that stenting 
is preferable in cases with relatively short life expectancy and more favourable with 
gastrojejunostomy in patients with longer life expectancy 135. However, the frequency of 
gastrojejunostomy has been decreasing with the introduction of stenting and both techniques 
still have failure of treatment. A retrospective study comparing partial stomach-partitioning 
gastrojejunostomy to gastrojejunostomy showed improved oral intake and lower frequency of 
postoperative delayed gastric emptying (DGE) 136. The result of this study is also in line with 
a meta-analysis of seven studies with 207 patients showing improved outcomes of partial 
stomach-partitioning gastrojejunostomy compared to conventional gastrojejunostomy in terms 
of improving DGE 137. 
Palliative resection can also be of value in the occurrence of bleeding or perforation. Bleeding 
can be controlled with radiotherapy or endoscopic therapy but in refractory bleeding there 
might be need for resection 138. For perforation, resection can also be warranted either in the 
setting of curative intention or palliation depending on the stage of disease139, 140. 
The value of palliative resection in terms of survival has been studied in a subgroup of patients 
in the large Dutch gastric cancer trial and show that for subgroup of patients younger than 70 
years of age and metastatic disease localized to one metastatic site, palliative resection 
increased median survival time with around 4 months 141. A study randomizing 86 patients to 
chemotherapy alone versus 89 patients to gastrectomy plus chemotherapy in the presence of 
one non-curable factor showed no advantage for gastrectomy plus chemotherapy 142. Two case 
series from Taiwan investigating the effects of palliative resection show some results of slightly 
better survival of palliative resection compared to no resection on palliative patients. But these 
are case series from single institutions and non-randomized 143, 144. 
1.3.5.2 Palliative oncological treatment 
Amongst newly diagnosed gastric cancer patients around 30 % are assessed as primarily with 
distant metastatic disease and only around 45-60% can undergo potentially curative resection 
145, 146. The high number of cases ineligible for curatively intended treatment warrants efficient 
palliative therapy. If tolerable, palliative chemotherapy may have a small survival advantage 
compared to best supportive care and increases overall median survival time with 
approximately 3 - 9 months 147-149. A randomised phase 3 study comparing a combination of 
trastuzumab and first line chemotherapy of capecitabine plus cisplatin or fluorouracil plus 
cisplatin versus chemotherapy alone for HER2 positive tumours showed a significant increased 
median overall survival of 13,8 months for the trastuzumab group versus 11,1 months for the 
chemotherapy alone group 150.  
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Another multicenter trial investigated for HER2 positive metastatic gastric cancer and 
gastroesophageal junction cancer patients the added effect of dual HER2 targeted therapy. The 
trial compared the addition of Pertuzumab to Trastuzumab and chemotherapy compared to 
Trastuzumab and chemotherapy alone. The results do not show any improved overall survival 
for the Pertuzumab group 151. 
A study on second line treatment compared Regorafenib to placebo and studied progression-
free survival as primary endpoint showed significant difference in favour for Regorafenib. 
However, the effect was very modest showing median progression free survival of 2.6 months 
compared to 0.9 months for Regorafenib and placebo respectively 152. 
Second line treatment with Irinotecan compared to best supportive care on patients that had 
progressed on first line treatment had a median survival of 4 months compared to 2,4 months 
respectively, the hazard ratio for death was reduced to 0.48 153. Although statistically 
significant, the actual clinical relevance and value of second-line therapy with those modest 
results can be questioned. 
 
1.4 FOLLOW UP 
There are no clear recommendations concerning follow-up after gastrectomy for cancer. Most 
Swedish centers will typically have 2-3 follow-up visits during the first year after gastrectomy 
to follow and manage weight-loss and different types of post-gastrectomy symptoms, such as 
early satiety and dumping. Thereafter yearly follow-up is common for up to five years after 
surgery but there is no evidence that it improves oncological outcomes because recurrences are 
very seldom possible to cure 154-156and early detection and treatment has not been shown to be 
beneficial. For patients with early gastric cancer that have undergone endoscopic resection, 
recurrences are possible to cure, and such patients are therefore subjected to regular re-
endoscopy. Eradication of H. Pylori infection is also important because this decreases the risk 
of developing metachronous gastric cancer 157. For patients that have undergone resection for 
gastric cancer, vitamin B12 supplementation should be initiated following total gastrectomy 
158. There are other studies correlating nutritional deficiencies to gastric surgery, however there 
are no clear recommendations on supplementation except for vitamin B12 159-161. 
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2 AIMS 
The aims of this thesis were: 
To evaluate the risk of Postoperative pancreatic fistula (POPF) and other postoperative 
complications after D2 gastrectomy with bursectomy for cancer in a high-volume tertiary unit. 
To investigate time trends and changes in some aspects of surgical treatment of gastric cancer 
in Sweden. 
To investigate the impact of extended lymphadenectomy during gastrectomy for cancer on 
postoperative morbidity and long-term survival. 
To investigate the effect of gastric cancer resection rates on survival for the entire gastric cancer 
population. 
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3 PATIENTS AND METHODS 
3.1 NATIONAL REGISTERS 
3.1.1 NREV 
The National Register for Oesophageal and Gastric Cancer (NREV) was started in 2006. The 
register aims to have complete coverage of all patients in Sweden diagnosed with oesophageal 
and gastric cancer. The register is run by a board of multidisciplinary health-care professionals 
with representatives from all of Sweden’s six health care regions and from the regional cancer 
centers. There are additional support staff maintaining the integrity of the register and it is also 
monitored by the six regional cancer centers. The register is developed from a national goal 
from the National Board of Health and Welfare to implement diagnose specific quality registers 
in order to monitor and evaluate as well as do research on the results and quality of the 
healthcare given in Sweden. 
Patients in the NREV are cross referenced with the Swedish Cancer Register continuously to 
maximize the coverage of NREV. A validation study has shown the validity of the data in the 
register to be 91% 162. The register has been updated during the last years and from 2018 now 
comprises five sections. The first section covers diagnostic data. The second section covers the 
surgical details of treatment. The third covers postoperative complications. The fourth has a 
subset of sections detailing oncological treatment from neoadjuvant, perioperative, adjuvant 
and palliative treatment and follow up. The fifth section covers quality of life details. 
The NREV publishes an annual report based on data from the previous year in the register to 
monitor changes in treatment pattern over the years and highlight regional differences in the 
care of gastric cancer patients 163. 
The board of NREV have regular meetings to improve the register and develop the register so 
that the data it contains are of highest possible quality. 
The register has a research committee that are responsible for assessing applications to perform 
research on the data in the register. 
To date, in the spring of 2020 there has been published thirteen peer-reviewed scientific reports 
based on data from the register 162, 164-175 and a fourteenth article in press. 
3.1.2 Swedish Cancer register 
A national register run by the National Board of Health and Welfare. There are roughly 60,000 
cases reported to the register each year. The cases refer to reported tumours and not individuals. 
The register was founded in 1958 with the purpose of creating a register to map and follow the 
incidence and prevalence of malignant diseases and change over time as well as a foundation 
for clinical and epidemiologic research. All pathologically verified tumours are mandated to 
be reported to the register separately by the pathologist and clinician and this is monitored in 
Sweden’s six regional cancer centers. There is near complete coverage of diagnosed cases 176. 
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3.1.3 National Patient register 
The register was established in 1964 and is administered by the National Board of Health and 
Welfare. It has complete coverage of inpatient data from 1987 and for specialized outpatient 
data from 2001. The register does not contain data on primary care outpatient data177. The 
register contains the ICD codes of main diagnosis and secondary diagnosis. The register has 
been used to obtain and determine the Charlson co-morbidity Index. 
3.1.4 National Register of Education 
The register (also integrated with Longitudinell integrationsdatabas för sjukförsäkrings- och 
arbetsmarknadsstudier (LISA)) is administered by Statistics Sweden. The first version of the 
register was from 1985. The register has since then been updated. The register has information 
on individuals highest completed degree. The register also has details on year of obtaining the 
degree. The data is obtained from the countries schools in the primary education system as well 
as from higher education system 178, 179. 
3.1.5 Total population Register and Cause of Death register 
These registers contain information on emigration, date of death and cause of death on all of 
Sweden’s population since 1968. The data is retrieved from the Swedish Tax Agency and based 
on the Swedish Census180. 
3.1.6 Swedish Prescribed Drug Register 
The register was started in 2005 and includes all prescribed drugs that are dispensed at Swedish 
pharmacies181, 182. 
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3.2 PAPER I 
3.2.1 Study design 
Retrospective single center cohort study. 
3.2.2 Data retrieval 
Data was retrieved from the county’s electronic patient chart system. Data covers extensive 
detail on patient baseline characteristics, treatment details and postoperative course and 
survival. The data were stored on institutional servers with censored patient information. 
3.2.3 Study population 
All gastric cancer patients that had a gastrectomy with D2 lymphadenectomy at Karolinska 
University Hospital between 2006 and June 2012. 
3.2.4 Main outcome measure 
The incidence and risk of postoperative pancreatic fistula (POPF) as defined by the 
International Study Group of Pancreatic Fistula (ISGPF) 183. 
3.2.5 Statistical analysis 
Data are presented as median with interquartile range. The Fisher exact test and Mann-Whitney 
U test were used for categorical and continuous variables. Multivariable analysis of risk factors 
was conducted with multivariable logistics regression. Statistical analysis was done with 
STATA/IC 12.1 software (StataCorp. LP, College Station, Texas, USA). 
3.2.6 Ethical approval 
The study has been approved by the Regional Ethics Committee (EPN Stockholm Dnr: 
2013/596-31/3). 
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3.3 PAPER II 
3.3.1 Study design 
National quality register study cross matched with other national healthcare registers. 
3.3.2 Study population 
All patients in Sweden with gastric cancer that had curative intended surgery (based on 
responsible surgeons’ opinion on treatment intent) from 2006-2013. 
3.3.3 Main outcome measure 
The main outcome was 30-day postoperative mortality and 30-day overall morbidity after 
surgery for gastric cancer as defined below. 
3.3.4 Secondary outcome measure 
90-day postoperative mortality: Mortality within 90 days of surgery. 
 
Postoperative complications as defined by 
Surgical complications 
Anastomotic insufficiency: Clinically significant leakage, pure radiologic signs without 
clinical correlation were not included. 
Bleeding: More than 2 L or need of reoperation. 
Abscess: Radiological or surgically proven collection of pus of at least 3 cm × 3 cm with 
clinical symptoms such as fever or pain. 
Other: Other complications prolonging hospital length of stay for at least 7 days. 
 
General complications 
Pneumonia: Radiological consolidations or opacities with clinical correlation with fever, 
dyspnoea or cough. 
Sepsis: Fever, chills and positive blood culture. 
Serious cardiovascular complications: New onset arrhythmia, myocardial infarction and 
stroke 
Pulmonary embolism: Radiologically proven and needing treatment 
Other: Other complications prolonging hospital length of stay for at least 7 days. 
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3.3.5 Definition of exposure 
Patients were categorized and classified to different extent of lymphadenectomy based on 
which stations had been reported as resected in NREV. The categorization and definition was 
based upon JGCA 3rd English version treatment guidelines 66 for gastric cancer and categorized 
to D0, D1 or D1+/D2. Modifications were made to D2 in total gastrectomy where omission of 
station 10 node still was categorized as D2. And D1 distal gastrectomy where omission of 
station 1 and 7 nodes still was classified as D1. 
3.3.6 Statistical analysis 
Data are presented as mean ± SD and actual count and percentage in parenthesis. Data are 
analysed with chi square test and Fisher exact test for categorical parametric and non-
parametric variables and ANOVA and Kruskall-Wallis for continuous parametric and non-
parametric variables. Risk factor analysis was performed with logistics regression and 
multivariable analysis with multivariable logistics regression. Variables used in the 
multivariable model were age, gender, BMI, ASA class, Charlson comorbidity index, tumour 
stage (TNM 7), surgical procedure, multivisceral resection, hospital volume and calendar year. 
Associations was presented as Odds ratio (OR) with 95% confidence interval (95% CI). All 
analyses were done using IBM SPSS Statistics (Version 22.0; IBM Corp., New York, USA). 
3.3.7 Ethical approval 
The study has been approved by the Regional Ethics Committee (EPN Stockholm Dnr: 
2013/596-31/3). 
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3.4 PAPER III 
3.4.1 Study design 
National quality register study cross matched with other national healthcare registers. 
3.4.2 Study population 
All patients in Sweden with gastric cancer which had curative intended surgery (based on 
responsible surgeons’ opinion on treatment intent) from 2006-2017. 
3.4.3 Main outcome measure 
The main outcome was overall survival after surgery. 
3.4.4 Definition of exposure 
Patients were categorized and classified to different extent of lymphadenectomy based on the 
reported lymph node stations in NREV. The categorization and definition were based upon 
JGCA 4th English version treatment guidelines 184 for gastric cancer and categorized to D0, D1, 
D1+ and D2. The exposure was grouped to D0/D1 and D1+/D2. 
3.4.5 Statistical analysis 
Data are presented as mean ± SD and actual count and percentage in parenthesis. Data are 
analysed with chi square test and Fisher exact test for categorical variables. Student t test was 
used for continuous variables. Overall survival was estimated using the Kaplan-Meier method 
with Log Rank test. Analysis in a multivariable model to estimate Hazard Ratio (HR) and 95% 
confidence interval (95% CI) was done using cox proportional hazard method. Variables used 
in the multivariable model were age, gender, ASA class, Charlson comorbidity index, tumour 
stage (TNM 8), surgical procedure, multivisceral resection, preoperative chemotherapy, 
education level and calendar year. All analyses were done using IBM SPSS Statistics (Version 
25.0; IBM Corp., New York, USA). 
3.4.6 Ethical approval 
The study has been approved by the Regional Ethics Committee (EPN Stockholm Dnr: 
2016/1486-32 and 2013/596-31/3) 
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3.5 PAPER IV 
3.5.1 Study design 
National quality register study cross matched with other national healthcare registers. 
3.5.2 Study population 
All patients in Sweden diagnosed with clinical M0 gastric cancer from 2006-2017. 
3.5.3 Main outcome measure 
The main outcome was overall survival from time of diagnosis in the entire cohort of gastric 
cancer patients. 
3.5.4 Definition of exposure 
Main exposure was the resection rate for the particular county of residence and year when the 
diagnosis was set for that patient regardless if the patient had a resection or not. This annual 
county resection rate was calculated by dividing the number of resected gastric cancers by the 
total number of gastric cancer cases diagnosed that year. Resection rate was stratified to three 
equal groups and compared and analysed for association with the main outcome measure. 
3.5.5 Statistical analysis 
Data are presented as mean ± SD and actual count and percentage in parenthesis. Analysis with 
chi square test and ANOVA was used for categorical and continuous variables respectively. 
Overall survival was estimated using the Kaplan-Meier method with Log Rank test. 
Multivariable analysis of risk factors and association to survival was done with Cox 
proportional hazard model to estimate Hazard Ratio (HR) and 95% confidence interval (95% 
CI). Variables used in multivariable model were resection rate, age, gender, clinical tumour 
stage, ASA class, Charlson comorbidity index, education level and multidisciplinary 
conference. All analyses were done using IBM SPSS Statistics (Version 26.0; IBM Corp., 
New York, USA). 
3.5.6 Ethical approval 
The study has been approved by the Regional Ethics Committee (EPN Stockholm Dnr: 
2016/1486-32 and 2013/596-31/3) 
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4 RESULTS 
4.1 PAPER I 
Identification through electronic hospital records yielded a total of 93 patients during the six-
and-a-half-year study period that had a D2 gastrectomy. One patient underwent concomitant 
total pancreatectomy and was excluded for analysis of risk to develop postoperative pancreatic 
fistula (POPF). This resulted in a population of 92 patients eligible for analysis. The complete 
flow chart for patient selection can be seen from Figure 2. 
 
 
Figure 2. Patient selection for Paper I. 
4.1.1 Patient demographics and treatment details 
In general patients were quite young and close to normal BMI. Their physical status as 
classified by ASA class was assessed as quite moderate as 84 patients (91%) were of ASA 
class 2-3. Neoadjuvant chemotherapy was given in roughly half of the patients and 31 patients 
(34%) had additional organ resection other than gastrectomy. Complete details of the patient 
demographics and baseline characteristics are presented in Table 2 and treatment details 
presented in Table 3. 
 
4.1.2 Postoperative complications 
In total the 30-day mortality was low (2 patients). General complication rate of Clavien 3b or 
higher occurred in 22 (24%) cases. Postoperative abscess occurred in 22 (24%) patients of 
which ten cases could be attributed to POPF. The overall POPF grade B or C occurred in 11 
(12%) cases. Details of complications are presented in Table 4. 
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Table 2. Patient demographics and baseline 
characteristics. 
 N = 92 
Age median (IQR) 66.5 (57–77) 
  
Gender  
Male 48 (52%) 
Female 44 (48%) 
  
BMI median (IQR) 25.2 (22.2–27.7) 
  
ASA class  
ASA I 4 (4.3%) 
ASA II 45 (48.9%) 
ASA III 39 (42.4%) 
ASA IV 2 (2.2%) 
Missing 2 (2.2%) 
  
Tumour stage  
Stage 0 4 (4.3%) 
Stage I 29 (31.5%) 
Stage II 34 (37.0%) 
Stage III 19 (20.7%) 
Stage IV 6 (6.5%) 
BMI body mass index, ASA American Society 
of Anaesthesiologists. Tumour stage 
according to TNM7. IQR Interquartile range. 
Values refer to actual count and percentage in 
parenthesis. 
Table 4. Postoperative complications. 
 n = 92 
30-day mortality 2 (2%) 
90-day mortality 9 (10%) 
POPF grade B/C 11 (12%) 
Anastomotic leakage a 11 (12%) 
Reoperation 18 (20%) 
Abscess 22 (24%) 
Pneumonia 7 (8%) 
Sepsis 13 (14%) 
Cardiovascular 10 (11%) 
Pulmonary embolism 6 (7%) 
  
Clavien score  
Clavien 0/1 31 (34%) 
Clavien 2 25 (27%) 
Clavien 3a 14 (15%) 
Clavien 3b 9 (10%) 
Clavien 4a 3 (3%) 
Clavien 4b 8 (9%) 
Clavien 5 2 (2%) 
Values refer to actual counts and 
percentage in parenthesis. a includes 
oesophagojejunal, gastrojejunal and 
duodenal bulb leakage. 
Table 3. Treatment details. 
 N = 92 
Surgical procedure  
Total gastrectomy 57 (62%) 
Distal gastrectomy 28 (30%) 
Pylorus-preserving gastrectomy 7 (8%) 
  
Neoadjuvant therapy  
Perioperative chemotherapy 45 (49%) 
No perioperative chemotherapy 47 (51%) 
  
Completeness of resection  
R0 72 (78%) 
R1 16 (17%) 
R2 4 (4%) 
  
Operation time a n = 91 263 (228-338) 
  
Bleeding b n = 78 500 (331-888) 
  
Lymphnode yield (median IQR) 21 (15-29) 
  
bursectomy n = 91 83 (90%) 
  
Additional organ resection c 31 (34%) 
Pancreaticoduodenectomy 4 (4%) 
Distal pancreaticosplenectomy 4 (4%) 
local pancreatic resection 2 (2%) 
Splenectomy 21 (23%) 
Other d 5 (7%) 
Values refer to actual counts and percentage in 
parenthesis. a median time in minutes and 
interquartile range in parenthesis. b bleeding in ml 
and interquartile range in parenthesis. c Some patients 
appear in more than one group. d includes colectomy, 
liver resection, cholecystectomy, adrenalectomy and 
small bowel resection. 
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4.1.3 Postoperative pancreatic fistula 
Age (p = 0.051), pancreatic resection (p < 0.01) and splenectomy (p = 0.016) were associated 
and identified as risk factors for developing POPF grade B or C. Although the occurrence of 
splenectomy was also associated with distal pancreatectomy in 4 cases. Multivariable analysis 
with multivariable logistics regression revealed that pancreatic resection with OR 156 (95% CI 
8-3047) and age with OR 1.2 (95% CI 1.0-1.3) remained as independent risk factors for 
development of POPF grade B or C and that splenectomy was not independently associated, 
OR 2.9 (95% 0.5-19.1) Table 5.  
 
Table 5. Univariable and multivariable risk factors for developing POPF grad B or C. 
Risk factor Univariable Multivariable 
 OR (95% CI) p-value OR (95% CI) p-value      
Age (year increment) 1.07 (1.0-1.1) 0.042 1.2 (1.0-1.3) 0.023      
Pancreatectomy     
No pancreatic resection ref  ref  
Pancreatic resection 45.5 (8.4-245.3) <0.01 156 (8-3047) <0.01 
     
Splenectomy     
No splenectomy ref  ref  
Splenectomy 5.3 (1.4-19.6) 0.013 2.9 (0.5-19.1) 0.260      
BMI 0.99 (0.8-1.2) 0.901        
Operative time (10 min 
increment) 1.0 (0.9-1.1) 0.881 
  
     
Bleeding (cl) 1.0 (1.0-1.0) 0.832        
Gender     
Female ref    
Male 0.7 (0.2-2.6) 0.635        
ASA class    
ASA I-II ref    
ASA III-IV 2.3 (0.6-8.6) 0.208        
Neoadjuvant chemotherapy    
No chemotherapy ref    
Chemotherapy 0.9 (0.2-3.0) 0.807        
Surgical procedure    
Distal gastrectomy ref    
Total gastrectomy 1.1 (0.3-4.0) 0.903        
T-stage     
T0-T2 ref    
T3-T4 1.1 (0.3-3.9) 0.888        
N-stage     
N0 ref    
N1-N3 2.3 (0.6-9.3) 0.244   
Univariable and multivariable logistics regression for risk factors associated for POPF 
grade B or C. 
  
 30 | RESULTS 
4.2 PAPER II 
During the study period from 2006-2013 a total of 1,101 patients were identified for analysis 
of lymphadenectomy and postoperative morbidity and mortality. Complete flow chart of 
patient selection can be seen from Figure 3. 
 
Figure 3. Patient selection for Paper II. Ineligible for lymphadenectomy 
analysis include local excisions, previous gastric resection, proximal or 
pylorus-preserving central gastrectomy, or unknown surgical procedure. 
 
4.2.1 Patient demographics and baseline characteristics 
There were in total 349 (31.7%) D0, 494 (44.9%) D1 and 258 (23.4%) D1+/D2 respectively 
and their baseline characteristics are found in Table 6. There were in general more D1+/D2 
performed later in the study period. It was more frequently performed in high volume hospitals 
and University hospitals. The tumour stage distribution was slightly unproportioned towards 
more advanced stage in the D1+/D2 group. The opposite can be seen in ASA class where there 
is slightly lower ASA class in the D1+/D2 group. 
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Table 6. Baseline characteristics of patients in Paper II. 
 All cases Extent of lymphadenectomy  
 (n=1101) D0 (n=349) D1 (n=494) D1+/D2 (n=258) p-value 
Age 69 ± 12 72 ± 11 70 ± 11 65 ± 12 <0.001 
Gender     0.013 
Female 473 (43.0%) 129 (37.0%) 233 (47.2%) 111 (43.0%)  
Male 628 (57.0%) 220 (63.0%) 261 (52.8%) 147 (57.0%)  
BMI 25.1 ± 4.5 24.7 ± 4.6 25.4 ± 4.5 25.2 ± 4.4 0.044 
Tumour stage  
   
0.032 
Stage 0-I 323 (29.3%) 104 (29.8%) 158 (32.0%) 61 (23.6%)  
Stage II 386 (35.1%) 129 (37.0%) 175 (35.4%) 82 (31.8%)  
Stage III 198 (18.0%) 51 (14.6%) 88 (17.8%) 59 (22.9%)  
Stage IV 48 (4.4%) 15 (4.3%) 21 (4.3%) 12 (4.7%)  
Missing 146 (13.3%) 50 (14.3%) 52 (10.5%) 44 (17.1%)  
ASA class  
   
0.033 
I 290 (26.3%) 87 (24.9%) 122 (24.7%) 81 (31.4%)  
II 540 (49.0%) 181 (51.9%) 232 (47.0%) 127 (49.2%)  
III 231 (21.0%) 66 (18.9%) 123 (24.9%) 42 (16.3%)  
IV 15 (1.4%) 6 (1.7%) 8 (1.6%) 1 (0.4%)  
Missing 25 (2.3%) 9 (2.6%) 9 (1.8%) 7 (2.7%)  
CCI  
 
  0.171 
0-2 590 (53.6%) 199 (57.0%) 250 (50.6%) 141 (54.7%)  
3 or higher 511 (46.4%) 150 (43.0%) 244 (49.4%) 117 (45.3%)  
Neoadjuvant chemotherapy  
 
  <0.001 
No 768 (69.8%) 288 (82.5%) 359 (72.7%) 121 (46.9%)  
Yes 327 (29.7%) 58 (16.6%) 132 (26.7%) 137 (53.1%)  
Missing 6 (0.5%) 3 (0.9%) 3 (0.6%) 0 (0.0%)  
Education level  
 
  0.123 
Less or equal to 9 years 458 (41.6%) 155 (44.4%) 206 (41.7%) 97 (37.6%)  
10-12 years 434 (39.4%) 142 (40.7%) 194 (39.3%) 98 (38.0%)  
More than 12 years 184 (16.7%) 45 (12.9%) 85 (17.2%) 54 (20.9%)  
Missing 25 (2.3%) 7 (2.0%) 9 (1.8%) 9 (3.5%)  
Hospital type  
 
  <0.001 
University hospital 496 (45.0%) 94 (26.9%) 203 (41.1%) 199 (77.1%)  
County hospital 492 (44.7%) 199 (57.0%) 245 (49.6%) 48 (18.6%)  
Small local hospital 113 (10.3%) 56 (16.0%) 46 (9.3%) 11 (4.3%)  
Hospital volume     <0.001 
Low volume (0-<5) 370 (33.6%) 184 (52.7%) 152 (30.8%) 34 (13.2%)  
Intermediate volume (5-<10) 527 (47.9%) 134 (38.4%) 303 (61.3%) 90 (34.9%)  
Moderately high (10-<15) 0 (0%) 0 (0%) 0 (0%) 0 (0%)  
High volume (15 or more) 204 (18.5%) 31 (8.9%) 39 (7.9%) 134 (51.9%)  
Operation year     <0.001 
2006-2007 231 (21.0%) 98 (42.4%) 98 (42.4%) 35 (15.2%)  
2008-2009 323 (29.3%) 113 (35.0%) 145 (44.9%) 65 (20.1%)  
2010-2011 282 (25.6%) 75 (26.6%) 142 (50.4%) 65 (23.0%)  
2012-2013 265 (24.1%) 63 (23.8%) 109 (41.1%) 93 (35.1%)  
Values show actual numbers and percentage in parenthesis. BMI Body Mass Index, ASA American Society of 
Anaesthesiologists, CCI Charlson Comorbidity Index. Categorical variables analysed with the Chi-square test. 
Continuous variables analysed by Kruskall-Wallis test. P-values refer to any significant difference between all 
three groups. 
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4.2.2 Operative details 
There was a discrepancy regarding the surgical details between the groups. There was more 
multivisceral resection, bursectomy and longer operative time in the D1+/D2 group as would 
be expected. There was not an increase in perioperative bleeding for total gastrectomy patients 
regardless of extent of lymphadenectomy but however significantly more bleeding for distal 
gastrectomy in D1+/D2 lymphadenectomy. Complete operative details can be seen from Table 
7. 
Table 7. Details of surgical procedure in Paper II. 
 All cases Extent of lymphadenectomy 
 (n=1101) D0 (n=349) D1 (n=494) D1+/D2 (n=258) p-value 
Surgical procedure     <0.001 
Total gastrectomy 518 (47.0%) 145 (41.5%) 169 (34.2%) 204 (79.1%)  
Distal gastrectomy 583 (53.0%) 204 (58.5%) 325 (65.8%) 54 (20.9%)  
Number of lymphnodes      
Total gastrectomy 22±15 (n=471) 
16±12 
(n=136) 
19±12 
(n=159) 
29±17 
(n=176) <0.001 
Distal gastrectomy 15±12 (n=530) 
12±11 
(n=190) 
15±11 
(n=293) 
24±14 
(n=47) <0.001 
Operative time (min)      
Total gastrectomy 303±125 (n=401) 
284±117 
(n=104) 
260±89 
(n=140) 
355±139 
(n=157) <0.001 
Distal gastrectomy 212±86 (n=464) 
208±110 
(n=155) 
207±71 
(n=259) 
245±63 
(n=50) <0.001 
Bleeding (millilitre)      
Total gastrectomy 713±596 (n=506) 
755±745 
(n=139) 
687±513 
(n=168) 
706±543 
(n=199) 0.731 
Distal gastrectomy 414±401 (n=566) 
368±400 
(n=192) 
433±417 
(n=320) 
463±284 
(n=54) <0.001 
Bursectomy      
Total gastrectomy 181 (35.2%) (n=514) 
38 (26.4%) 
(n=144) 
34 (20.4%) 
(n=167) 
109 (53.7%) 
(n=203) <0.001 
Distal gastrectomy 104 (18.1%) (n=574) 
19 (9.5%) 
(n=200) 
50 (15.6%) 
(n=321) 
35 (66.0%) 
(n=53) <0.001 
Multivisceral resection      
Total gastrectomy 191 (37.1%) (n=515) 
47 (32.9%) 
(n=143) 
39 (23.1%) 
(n=169) 
105 (51.7%) 
(n=203) <0.001 
Distal gastrectomy 48 (8.2%) (n=582) 
15 (7.4%) 
(n=203) 
28 (8.6%) 
(n=325) 
5 (9.3%) 
(n=54) 0.831
* 
Values show actual numbers and percentage in parentheses. Continuous variables analysed by Kruskall-Wallis 
test. Categorical variables analysed with the Chi-square test. P-values refer to any significant difference between 
all three groups. Multivisceral resections included concomitant resection of either colon, diaphragm, oesophagus 
and thoracic duct, liver segment, spleen, pancreas, gallbladder, small bowel, adrenal gland or other organs*. 
Fisher’s exact test due to low expected counts.  
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4.2.3 Lymphnode yield 
There was a significant difference in the lymphnode yield between the three groups. The 
lymphnode yield was highest 29 ± 17 for D1+/D2 total gastrectomy as expected and lowest for 
D0 distal gastrectomy 12 ± 11. Distribution of lymphnode yield for each procedure can be seen 
from Figure 4. 
 
Figure 4. Boxplot of number of lymphnodes resected. Presented for lymphadenectomy and surgical procedure. 
Line represents median and box represents IQR. Whiskers represents 1.5 times the IQR. Outliers are not shown 
in the graph. Statistical inference with Kruskall-Wallis test between all groups, p < 0.001. 
 
4.2.4 Postoperative complications 
The overall 30-day mortality was 2.8% and 90-day mortality was 5.9%. The highest 
postoperative mortality occurred in D0 lymphadenectomy. The overall morbidity rate was 
26.9% and there was a significant difference and higher morbidity for D1+/D2 
lymphadenectomy. For specific complications there was significantly higher pulmonary 
embolism rates in D1+/D2 lymphadenectomy as well as reintervention with endoscopic stent 
placement in D1+/D2 lymphadenectomy. Details of postoperative complications can be seen 
from Table 8. 
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Table 8. Association between postoperative mortality or complications and different extent of 
gastric cancer lymphadenectomy in Paper II. 
  All cases Extent of lymphadenectomy 
  (n = 1101) D0 (n = 349) D1 (n = 494) 
D1+/D2 
(n = 258) p-value 
30-day mortality 31 (2.8%) 20 (5.7%) 4 (0.8%) 7 (2.7%) <0.001 
90-day mortality 65 (5.9%) 29 (8.3%) 21 (4.3%) 15 (5.8%) 0.048 
Overall complication 296 (26.9%) 89 (25.5%) 124 (25.1%) 83 (32.2%) 0.017 
General complication 178 (16.2%) 57 (16.3%) 74 (15.0%) 47 (18.2%) 0.304 
Pneumonia 52 (4.7%) 17 (4.9%) 28 (5.7%) 7 (2.8%) 0.250 
Sepsis 45 (4.1%) 10 (2.9%) 24 (4.9%) 11 (4.3%) 0.319 
Cardiovascular 
complication 36 (3.3%) 12 (3.4%) 17 (3.4%) 7 (2.8%) 0.919 
Pulmonary embolism 12 (1.1%) 0 (0.0%) 5 (1.0%) 7 (2.8%) 0.003* 
Other general 
complication 73 (6.6%) 25 (7.2%) 28 (5.7%) 20 (7.8%) 0.393 
Missing 84 (7.6%) 19 (5.4%) 33 (6.7%) 32 (12.4%)  
Surgical complication 190 (17.3%) 52 (14.9%) 86 (17.4%) 52 (20.2%) 0.096 
Bleeding 34 (3.1%) 13 (3.7%) 14 (2.8%) 7 (2.8%) 0.761 
Anastomotic 
insufficiency 41 (3.7%) 10 (2.9%) 16 (3.2%) 15 (5.8%) 0.073 
Abscess 60 (5.4%) 13 (3.7%) 29 (5.9%) 18 (7.0%) 0.125 
Other surgical 
complication 88 (8.0%) 23 (6.6%) 45 (9.1%) 20 (7.8%) 0.391 
Missing 86 (7.8%) 20 (5.7%) 33 (6.7%) 33 (12.8%)  
Reintervention      
Reoperation 107 (9.7%) 32 (9.2%) 48 (9.7%) 27 (10.5%) 0.688 
Stent 15 (1.4%) 2 (0.6%) 5 (1.0%) 8 (3.1%) 0.017* 
Values show actual numbers and percentage in parentheses. Variables analysed with Chi-square test. P-values 
refer to any significant difference between all three groups. * Fisher’s exact test due to low expected counts. 
 
4.2.5 Risk factors for mortality and complications 
To assess the risk of overall 30-day complication and 90-day mortality logistics regression was 
performed. The results of univariable and multivariable analysis can be seen from Table 9 and 
10. For both 30-day overall complication and 90-day mortality there is no increased risk of 
D1+/D2 lymphadenectomy in multivariable analysis. The analysis also reveals that age, male 
gender, total gastrectomy, MVR, high hospital volume, calendar year (2012-2013 vs 2006-
2007) is independently associated with higher risk of 30-day complication, Table 9. High 
hospital volume along with surgery late in the study period is somewhat conflicting to be 
associated with higher risk of complication. They are both associated with more D1+/D2 being 
performed and more MVR. There are some colinearity for these variables and despite analysis 
in multivariable model there could be some residual confounding left. 
For 90-day mortality higher ASA class and MVR were other risk factors independently 
associated with increased risk, Table 10.   
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Table 9. Univariable and multivariable risk factor analysis for overall 30-day complication 
Risk factor Univariable Multivariable 
 OR (95% CI) p-value OR (95% CI) p-value 
Extent of lymphadenectomy     
D0 ref  ref  
D1 1.0 (0.73-1.37) 0.982 1.08 (0.77-1.52) 0.657 
D1+/D2 1.57 (1.09-2.26) 0.015 1.04 (0.66-1.63) 0.871 
Age     
≤ 60 ref  ref  
61-70 1.42 (0.94-2.16) 0.099 1.71 (1.09-2.67) 0.019 
71-80 1.98 (1.34-2.94) <0.001 2.48 (1.60-3.85) <0.001 
> 80 1.60 (1.01-2.53) 0.046 2.22 (1.31-3.75) 0.003 
BMI     
1st quartile ref  ref  
2nd quartile 0.83 (0.55-1.26) 0.383 0.76 (0.49-1.19) 0.229 
3rd quartile 1.07 (0.72-1.61) 0.727 1.05 (0.69-1.62) 0.818 
4th quartile 1.05 (0.70-1.58) 0.805 1.04 (0.67-1.60) 0.868 
Missing 0.95 (0.58-1.56) 0.845 1.10 (0.65-1.87) 0.712 
Gender     
Female ref  ref  
Male 1.44 (1.09-1.90) 0.010 1.42 (1.05-1.90) 0.021 
ASA class     
ASA 1-2 ref  ref  
ASA 3-4 1.60 (1.17-2.19) 0.004 1.36 (0.96-1.94) 0.083 
Missing 1.57 (0.65-3.80) 0.315 1.40 (0.54-3.65) 0.492 
CCI     
0-2 ref  ref  
3 or higher 1.18 (0.90-1.54) 0.242 1.12 (0.84-1.51) 0.443 
Tumour stage     
Stage 0-I ref  ref  
Stage II 1.26 (0.90-1.77) 0.174 1.15 (0.81-1.63) 0.451 
Stage III 1.62 (1.10-2.38) 0.015 1.16 (0.76-1.77) 0.487 
Stage IV 1.54 (0.81-2.96) 0.191 1.23 (0.60-2.52) 0.574 
Missing 1.58 (0.88-2.84) 0.124 1.35 (0.72-2.53) 0.348 
Surgical procedure     
Total gastrectomy ref  ref  
Distal gastrectomy 0.58 (0.44-0.77) <0.001 0.60 (0.43-0.83) 0.002 
MVR     
No ref  ref  
Yes 1.86 (1.36-2.55) <0.001 1.56 (1.09-2.24) 0.016 
Hospital volume     
<15 ref  ref  
≥15 1.79 (1.28-2.51) 0.001 1.62 (1.08-2.44) 0.020 
Calendar year     
2006-2007 ref  ref  
2008-2009 0.91 (0.61-1.35) 0.638 0.95 (0.63-1.45) 0.828 
2010-2011 1.13 (.075-1.68) 0.565 1.16 (0.75-1.79) 0.496 
2012-2013 1.71 (1.14-2.55) 0.009 1.74 (1.12-2.72) 0.014 
BMI Body Mass Index, ASA American Society of Anaesthesiologists. CCI Charlson comorbidity index. MVR 
multivisceral resection. Multivariable model includes all variables in the univariable list. 
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Table 10. Univariable and multivariable risk factor analysis for 90-day mortality. 
Risk factor Univariable Multivariable 
 OR (95% CI) p-value OR (95% CI) p-value 
Extent of lymphadenectomy     
D0 ref  ref  
D1 0.49 (0.28-0.87) 0.016 0.46 (0.24-0.86) 0.015 
D1+/D2 0.68 (0.36-1.30) 0.243 0.50 (0.21-1.19) 0.116 
Age     
≤ 60 ref  ref  
61-70 1.21 (0.46-3.16) 0.701 1.14 (0.42-3.12) 0.798 
71-80 2.56 (1.10-5.98) 0.030 1.86 (0.73-4.72) 0.192 
> 80 3.99 (1.65-9.66) 0.002 2.92 (1.07-7.99) 0.037 
BMI     
1st quartile ref  ref  
2nd quartile 0.54 (0.24-1.19) 0.127 0.64 (0.28-1.49) 0.299 
3rd quartile 0.97 (0.49-1.93) 0.931 1.16 (0.54-2.48) 0.702 
4th quartile 0.48 (0.21-1.10) 0.082 0.57 (0.24-1.38) 0.215 
Missing 1.17 (0.53-2.55) 0.701 1.36 (0.58-3.17) 0.480 
Gender     
Female ref  ref  
Male 0.87 (0.53-1.44) 0.592 0.79 (0.45-1.36) 0.390 
ASA class     
ASA 1-2 ref  ref  
ASA 3-4 3.48 (2.09-5.82) <0.001 3.45 (1.89-6.30) <0.001 
Missing 1.01 (0.13-7.67) 0.995 1.05 (0.13-8.62) 0.968 
CCI     
0-2 ref  ref  
3 or higher 1.68 (1.01-2.79) 0.047 1.60 (0.91-2.83) 0.104 
Tumour stage     
Stage 0-I ref  ref  
Stage II 1.30 (0.64-2.66) 0.468 1.29 (0.60-2.76) 0.519 
Stage III 2.83 (1.38-5.79) 0.004 3.28 (1.46-7.39) 0.004 
Stage IV 2.17 (0.68-6.95) 0.193 3.00 (0.84-10.78) 0.092 
Missing 1.20 (0.47-3.08) 0.703 1.57 (0.56-4.40) 0.392 
Surgical procedure     
Total gastrectomy ref  ref  
Distal gastrectomy 0.75 (0.45-1.24) 0.259 0.94 (0.50-1.78) 0.848 
MVR     
No ref  ref  
Yes 2.28 (1.35-3.87) 0.002 2.35 (1.24-4.45) 0.009 
Hospital volume     
<15 ref  ref  
≥15 1.34 (0.74-2.45) 0.332 1.63 (0.76-3.50) 0.212 
Calendar year     
2006-2007 ref  ref  
2008-2009 0.97 (0.50-1.85) 0.915 0.97 (0.48-1.99) 0.943 
2010-2011 0.66 (0.32-1.36) 0.260 0.66 (0.29-1.47) 0.304 
2012-2013 0.55 (0.25-1.19) 0.127 0.48 (0.20-1.16) 0.104 
BMI Body Mass Index, ASA American Society of Anaesthesiologists. CCI Charlson comorbidity index. MVR 
multivisceral resection. Multivariable model includes all variables in the univariable list. 
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4.3 PAPER III 
During the study period of 2006-2017 a total of 6154 patients were identified as having gastric 
cancer. 1677 (27%) of which were eligible for lymphadenectomy analysis on survival. Flow 
chart for patient selection can be seen from Figure 5. 
 
 
Figure 5. Patient selection for paper III. 
 
4.3.1 Trends in surgery 
Traditionally surgery for gastric cancer has been done in almost all hospitals during the last 
decade, centralization has taken place and number of hospitals performing gastric cancer 
surgery is decreasing. In 2007 the number of hospitals performing curative intended resections 
for gastric cancer were as high as 45 and has been decreasing to 12 in 2017. The number of 
resections performed have been around 150 annually and then decreased to around 120 for 
2014 to 2016. The data for 2017 is incomplete as all registrations are not yet in the register as 
of the time of data withdrawal, Figure 6. The centralization process has also shifted the 
procedures to university hospitals over the study period and the frequency of D1+/D2 
procedures have increased later in the period as seen in Figure 7. 
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Figure 6. Number of cases and number of hospitals performing surgery during the study period. Bar represent 
number of resections for respective year and follows y-axis on left side. Line represents number of hospitals 
performing curative intended resection for respective year and follows y-axis on right side. 
 
 
Figure 7. Distribution of resections in hospital type and extent of lymphadenectomy during the study period. 
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4.3.2 Patient demographics 
During the study period there was 1206 (72%) D0/D1 and 471 (28%) D1+/D2 performed. 
Complete baseline characteristics of the patients are presented in Table 11. The D1+/D2 cases 
are generally younger, have a higher level of education, a slightly lower ASA class and had a 
more advanced tumour stage. 
 
Table 11. Baseline characteristics of patients in Paper III. 
 D0/D1 (n=1206) D1+/D2 (n=471) Total (n=1677) p-value 
Age (mean ± SD) 70 ± 11 65 ± 12 69 ± 12 <0.001 
BMI (mean ± SD) 25.1 ± 4.45 25.2 ± 4.43 25.2 ± 4.44 0.682 
     
Gender    0.602 
Male 698 (57.9%) 266 (56.5%) 964 (57.5%)  
Female 508 (42.1%) 205 (43.5%) 713 (42.5%)  
     
ASA class    <0.001* 
ASA I 310 (25.7%) 168 (35.7%) 478 (28.5%)  
ASA II 591 (49.0%) 223 (47.3%) 814 (48.5%)  
ASA III 252 (20.9%) 66 (14.0%) 318 (19.0%)  
ASA IV 24 (2.0%) 3 (0.6%) 27 (1.6%)  
Missing 29 (2.4%) 11 (2.3%) 40 (2.4%)  
     
Clinical tumour stage    <0.001 
Stage I 402 (33.3%) 120 (25.5%) 522 (31.1%)  
Stage II 312 (25.9%) 167 (35.5%) 479 (28.6%)  
Stage III 149 (12.4%) 100 (21.2%) 249 (14.8%)  
Stage IV 27 (2.2%) 17 (3.6%) 44 (2.6%)  
Missing 316 (26.2%) 67 (14.2%) 383 (22.8%)  
     
CCI    0.655 
0-1 400 (33.2%) 147 (31.2%) 547 (32.6%)  
2 195 (16.2%) 83 (17.6%) 278 (16.6%)  
3 or higher 611 (50.7%) 241 (51.2%) 852 (50.8%)  
     
Education level    <0.001 
Less or equal to 9 years 474 (39.3%) 149 (31.6%) 623 (37.1%)  
10 to 12 years 455 (37.7%) 193 (41.0%) 648 (38.6%)  
More than 12 years 186 (15.4%) 111 (23.6%) 297 (17.7%)  
Missing 91 (7.5%) 18 (3.8%) 109 (6.5%)  
     
Tumour location    <0.001 
GOJ Siewert III 37 (3.1%) 52 (11.0%) 89 (5.3%)  
Upper 39 (3.2%) 34 (7.2%) 73 (4.4%)  
Middle 386 (32.0%) 205 (43.5%) 591 (35.2%)  
Lower 625 (51.8%) 123 (26.1%) 748 (44.6%)  
Whole 25 (2.1%) 23 (4.9%) 48 (2.9%)  
Missing 94 (7.8%) 34 (7.2%) 128 (7.6%)  
     
Calendar year of surgery    <0.001 
2006-2009 468 (38.8%) 98 (20.8%) 566 (33.8%)  
2010-2013 469 (38.9%) 179 (38.0%) 648 (38.6%)  
2014-2017 269 (22.3%) 194 (41.2%) 463 (27.6%)  
Values show actual numbers and percentage in parenthesis. BMI Body Mass Index, ASA American Society of 
Anaesthesiologists, CCI Charlson comorbidity index. Continuous variables analysed with student t test and 
categorical variables analysed with the Chi-square test except for cases marked with * where Fisher’s Exact 
test was used. 
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4.3.3 Surgical treatment details and complications 
The treatment details for the two groups are presented in Table 12. The D1+/D2 group had a 
higher proportion of total gastrectomy, preoperative chemotherapy and multivisceral resection 
(including pancreaticosplenectomy and splenectomy). The 30- and 90-day postoperative 
mortality did not differ between the groups but D1+/D2 lymphadenectomy yielded more 
lymphnodes and also carried a higher postoperative complication rate, Table 13. 
 
Table 12. Surgical details of patients submitted to either a limited D0/D1 lymphadenectomy or 
a more extensive D1+/D2 dissection. 
  D0/D1 (n=1206) D1+/D2 (n=471) Total (n=1677) p-value 
Surgical procedure    <0.001 
Distal gastrectomy 770 (63.8%) 120 (25.5%) 890 (53.1%)  
Total gastrectomy 436 (36.2%) 351 (74.5%) 787 (46.9%)  
     
Laparoscopic surgery    0.111 
No 1171 (97.1%) 450 (95.5%) 1621 (96.7%)  
Yes 35 (2.9%) 21 (4.5%) 56 (3.3%)  
     
Preoperative 
chemotherapy    <0.001 
No 870 (72.1%) 191 (40.6%) 1061 (63.3%)  
Yes 322 (26.7%) 280 (59.4%) 602 (35.9%)  
Missing 14 (1.2%) 0 (0.0%) 14 (0.8%)  
     
Multivisceral resection    <0.001 
No 1004 (83.9%) 312 (66.5%) 1316 (79.0%)  
Yes 193 (16.1%) 157 (33.5%) 350 (21.0%)  
     
Pancreaticosplenectomy    <0.001 
No 1178 (98.4%) 446 (95.1%) 1624 (97.5%)  
Yes 19 (1.6%) 23 (4.9%) 42 (2.5%)  
     
Splenectomy    <0.001 
No 1118 (93.4%) 369 (78.7%) 1487 (89.3%)  
Yes 79 (6.6%) 100 (21.3%) 179 (10.7%)  
     
Emergency operation    0.457 
No 1162 (97.0%) 460 (97.7%) 1622 (97.2%)  
Yes 36 (3.0%) 11 (2.3%) 47 (2.8%)  
Values show actual numbers and percentage in parenthesis. Variables analysed with the Chi-square test. 
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Table 13. Lymph node yield and postoperative complications in patients submitted to either a 
limited D0/D1 lymphadenectomy or a more extensive D1+/D2 dissection. 
  D0/D1 (n=1206) D1+/D2 (n=471) Total (n=1677) p-value 
Number of lymphnodes 
(mean ± SD)     
Distal gastrectomy 16 ± 12 (n=693) 25 ± 15 (n=106) 17 ± 13 (n=799) <0.001 
Total gastrectomy 19 ± 13 (n=398) 31 ± 18 (n=301) 24 ± 16 (n=699) <0.001 
     
30-day postop mortality     
No 1179 (97.8%) 460 (97.7%) 1639 (97.7%) 0.905 
Yes 27 (2.2%) 11 (2.3%) 38 (2.3%)  
     
90-day postop mortality     
No 1143 (94.8%) 451 (95.8%) 1594 (95.1%) 0.407 
Yes 63 (5.2%) 20 (4.2%) 83 (4.9%)  
     
Overall complication     
No 811 (73.4%) 264 (64.4%) 1075 (71.0%) 0.001 
Yes 294 (26.6%) 146 (35.6%) 440 (29.0%)  
Values show actual numbers and percentage in parenthesis. Continuous variables analysed with student t test and 
categorical variables analysed with the Chi-square test. 
 
4.3.4 Survival 
Overall stage specific survival can be seen from Figure 8A. The total overall median survival 
for all patients subjected to curative intended surgery is 39 months (95% CI 35-43). Regional 
differences in survival is presented in Figure 8B with the highest median overall survival in 
one region of 51 months (95% CI 23-79) and the lowest median overall survival in another 
region of 29 months (95% CI 24-35) log rank test p = 0.001. 
Survival in respect to hospital volume is presented in Figure 8C. The results show incremental 
increase in survival curve for higher annual hospital volume. Where patients operated on in 
high volume hospitals (more than 15 cases per year) had a median overall survival of 49 months 
(95% CI 35-62) and patients in low volume hospitals (less than 5 cases per year) had a median 
overall survival of 37 months (95% CI 31-42) log rank test p = 0.095. 
Preoperative chemotherapy in crude survival analysis increased overall survival and is 
presented in Figure 8D. The overall median survival is 52 months (95% CI 39-65) for 
preoperative chemotherapy and 34 months (95% CI 30-38) for no preoperative chemotherapy, 
log rank test p < 0.001. 
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Figure 8. Overall survival for curatively resected patients presented in various patient specific and treatment 
specific details. A. Clinical stage specific survival with TNM8 definition, Log rank test p < 0.001 B. According to 
geographical region of treatment in Sweden, Log rank test p = 0.001. C. Annual hospital volume, Log rank test p 
= 0.095. D. With and without preoperative chemotherapy, Log rank test p < 0.001. 
 
4.3.5 Lymphadenectomy and survival 
Overall median survival was 41 months (95% CI 30-53) and 5-year survival was 44% for 
D1+/D2 lymphadenectomy. The median survival was 38 months (95% CI 34-43) and 5-year 
survival was 39% for D0/D1 respectively, log rank test p = 0.116, Figure 9. Multivariable Cox 
proportional hazard revealed D1+/D2 was associated with lower risk of death with hazard 
ratio of 0.81 (95% CI 0.68-0.95) p = 0.012, Table 14. 
  
No. at risk
Stage I 522 360 241 145 85 37 4
Stage II 479 253 131 76 41 16 0
Stage III 249 94 40 24 14 9 1
Stage IV 44 17 11 7 3 0 0
Missing 383 214 138 77 46 21 3
No. at risk
Region 1 364 211 121 75 45 17 2
Region 2 316 170 97 51 29 10 2
Region 3 340 201 128 73 41 21 1
Region 4 178 104 71 49 25 13 1
Region 5 231 120 78 47 28 16 2
Region 6 247 131 65 33 20 6 0
No. at risk
0-<5 643 386 254 164 103 54 6
5-<10 331 181 104 63 40 16 2
10-<15 324 166 89 41 19 4 0
15 or more 378 204 113 60 26 9 0
No. at risk
No CT 1061 590 352 219 135 65 8
CT 602 342 205 106 51 15 0
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Figure 9. Overall survival for curatively resected patients for different extent of lymphadenectomy. 
 
 
Table 14. Cox proportional hazard analysis of the impact of lymphadenectomy on survival.  
D1+/D2 vs D0/D1 (HR, 95 % CI) 
 
 Crude p-value Adjusted p-value 
All cases 0.89 (95% CI 0.77-1.03) 0.107 0.81 (95% CI 0.68-0.95) 0.012 
 
    
Distal 
gastrectomy 0.61 (95% CI 0.44-0.84) 0.003 0.75 (95% CI 0.54-1.06) 0.100  
    
Total 
gastrectomy 0.86 (95% CI 0.72-1.03) 0.108 0.85 (95% CI 0.70-1.04) 0.111 
Adjusted for age, gender, Charlson comorbidity index, ASA class, clinical tumour stage, surgical procedure (in 
analysis with all cases), multivisceral resection, preoperative chemotherapy, education level and calendar year of 
surgery. 
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4.4 PAPER IV 
During the study period of 2006-2017 a total of 6154 patients were identified as having gastric 
cancer. Clinical M1 and Mx cases were excluded resulting in 3465 cases left for analysis. Flow 
chart for patient selection can be seen from Figure 10. 
 
 
Figure 10. Patient selection for paper IV. 
 
The total number of patients resected were 1934 (55.8%). There was a large geographical 
variation in between counties regarding their annual county specific resection rate which varied 
from 0% - 100%. The 5th to 95th percentile ranged from 22% - 80% and the IQR was 41% - 
63%. 
4.4.1 Patient demographics and resection rate 
The patients assigned resection rate were grouped to tertiles resulting in low, intermediate and 
high group. The distribution of patients for these groups were 1261, 1141 and 1063 patients 
respectively. The resection rate ranged from 0% – 50.0%, 50.1% - 62.5% and 62.6% - 100% 
respectively. The complete details of baseline characteristics of patients are presented in Table 
15. 
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Table 15. Baseline characteristics of patients. 
  Resection rate 
 
Low 
(0%-50.0%) 
(n=1261) 
Intermediate 
(50.1%-62.5%) 
(n=1141) 
High 
(62.6%-100%) 
(n=1063) 
All patients 
(n=3465) 
p-value 
Age a  73 ± 12 72 ± 12 72 ± 12 72 ± 12 0.064b 
      
Gender      
Male 747 (59.2%) 652 (57.1%) 613 (57.7%) 2012 (58.1%) 0.554 
Female 514 (40.8%) 489 (42.9%) 450 (42.3%) 1453 (41.9%) 
 
      
ASA class      
ASA I-II 729 (57.9%) 741 (65.0%) 676 (63.6%) 2146 (62.0%) <0.001 
ASA III-IV 382 (30.3%) 371 (32.5%) 322 (30.3%) 1075 (31.0%) 
 
Missing 149 (11.8%) 28 (2.5%) 65 (6.1%) 242 (7.0%) 
 
      
Clinical 
tumour stage 
     
Stage I 237 (18.8%) 289 (25.3%) 304 (28.6%) 830 (24.0%) <0.001 
Stage II 356 (28.2%) 329 (28.8%) 283 (26.6%) 968 (27.9%) 
 
Stage III 242 (19.2%) 234 (20.5%) 182 (17.1%) 658 (19.0%) 
 
Stage IVa 18 (1.4%) 7 (0.6%) 3 (0.3%) 28 (0.8%) 
 
Missing 408 (32.4%) 282 (24.7%) 291 (27.4%) 981 (28.3%) 
 
      
CCI     0.003 
0-1 424 (33.6%) 362 (31.7%) 385 (36.2%) 1171 (33.8%)  
2 177 (14.0%) 202 (17.7%) 192 (18.1%) 571 (16.5%)  
3 or more 660 (52.3%) 577 (50.6%) 486 (45.7%) 1723 (49.7%)  
      
Education 
level 
     
Less or equal 
to 9 years 
519 (41.2%) 430 (37.7%) 414 (38.9%) 1363 (39.3%) <0.001 
10 to 12 
years 
465 (36.9%) 431 (37.8%) 341 (32.1%) 1237 (35.7%) 
 
More than 12 
years 
188 (14.9%) 186 (16.3%) 139 (13.1%) 513 (14.8%) 
 
Missing 89 (7.1%) 94 (8.2%) 169 (15.9%) 352 (10.2%) 
 
      
MDT      
No 487 (38.6%) 295 (25.9%) 439 (41.3%) 1221 (35.2%) <0.001 
Yes 764 (60.6%) 828 (72.6%) 570 (53.6%) 2162 (62.4%) 
 
Missing 10 (0.8%) 18 (1.6%) 54 (5.1%) 82 (2.4%)  
      
Resected 
patients 
     
No resection 773 (61.3%) 482 (42.2%) 276 (26.0%) 1531 (44.2%) <0.001 
Resection 488 (38.7%) 659 (57.8%) 787 (74.0%) 1934 (55.8%)  
ASA American society of Anaesthesiologists, CCI Charlson comorbidity index, MDT multidisciplinary therapy 
conference. Values show actual count and percentage. a Mean ± SD. Statistical inference with chi-square test, b 
ANOVA. 
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4.4.2 Survival 
Overall median survival was 14.2, 20.9 and 21.9 months respectively for low, intermediate and 
high actual resection rate, Log Rank test p < 0.001. The survival graph can be seen in Figure 
11. 
In multivariable analysis with cox proportional hazard intermediate and high tertiles compared 
to low tertiles has better survival. The complete analysis can be seen in Table 16 revealing 
other independently associated factors related to survival. 
 
Figure 11. Overall survival from diagnosis according to actual resection rate tertiles, Log rank test p < 0.001. 
  
No. at risk
Low 1260 599 333 220 156 109 82 63 57 25 12 8 3
Intermediate 1140 716 471 343 245 178 130 87 64 48 28 12 0
High 1062 688 485 364 307 253 214 160 122 100 66 38 13
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Table 16. Cox proportional hazard on overall survival. 
 Univariable analysis  Multivariable analysis 
 HR 95% CI p-value  HR 95% CI p-value 
Resection rate        
Low 
(0%-50.0%) 
ref - -  ref - - 
Intermediate 
(50.1%-62.5%) 
0.75 0.68-0.83 <0.001  0.81 0.74-0.90 <0.001 
High 
(62.6%-100%) 
0.74 0.68-0.82 <0.001  0.80 0.73-0.88 <0.001 
        
Age        
per year 
increment 
1.04 1.03-1.04 <0.001  1.03 1.02-1.03 <0.001 
        
Gender        
Male ref - -  ref - - 
Female 0.98 0.91-1.06 0.624  1.02 0.94-1.10 0.683 
        
ASA        
I-II ref - -  ref - - 
III-IV 1.93 1.78-2.10 <0.001  1.52 1.39-1.66 <0.001 
Missing 1.20 1.00-1.46 0.055  1.12 0.91-1.37 0.289 
        
Clinical tumour 
stage 
       
Stage I ref - -  ref - - 
Stage II 1.79 1.59-2.01 <0.001  1.92 1.71-2.17 <0.001 
Stage III 2.54 2.24-2.88 <0.001  2.96 2.60-3.36 <0.001 
Stage IVa 4.50 2.96-6.85 <0.001  4.95 3.22-7.63 <0.001 
Missing 2.28 2.04-2.56 <0.001  1.98 1.76-2.22 <0.001 
        
CCI        
0-1 ref - -  ref - - 
2 1.01 0.90-1.14 0.821  0.98 0.87-1.10 0.709 
3 or more 1.21 1.11-1.32 <0.001  1.04 0.95-1.14 0.353 
        
Education level        
Less or equal to 
9 years 
ref - -  ref - - 
10 to 12 years 0.84 0.77-0.92 <0.001  0.98 0.90-1.08 0.720 
More than 12 
years 
0.71 0.63-0.81 <0.001  0.96 0.84-1.09 0.511 
Missing 1.44 1.27-1.63 <0.001  1.20 1.05-1.37 0.006 
        
MDT        
No ref - -  ref - - 
Yes 0.66 0.61-0.71 <0.001  0.77 0.71-0.84 <0.001 
Missing 0.66 0.51-0.84 0.001  0.90 0.69-1.17 0.425 
ASA American society of Anaesthesiologists, CCI Charlson comorbidity index, MDT multidisciplinary therapy 
conference. Multivariable Cox proportional hazard regression model include all variables in univariable list. 
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5 DISCUSSION 
5.1 RETROSPECTIVE SINGLE CENTER STUDIES  
Paper I is a single center retrospective study. Like all single center retrospective studies it has 
its inherent limits with selection bias and poor generalizability. However, it has a strong internal 
validity and also show the true results of that particular center. Regarding the outcome of 
postoperative pancreatic fistula, there are no missing cases. 
 
5.2 REGISTER BASED STUDIES 
As in all register-based studies the quality of the research is dependent on the validity and 
accuracy of the data. Sweden has a long history of national registers and register based studies. 
What these studies may lack in specific detail, is compensated by volume of patients and follow 
up time. The NREV is a fairly “young” register but a validation study 162 has shown a coverage 
of over 95% and a validity of data of over 91%. In addition to this register, additional data 
needed for patients can be obtained through other national registers such as the Cancer-, 
Patient-, Total population-, Cause of death-, Prescribed drug register, and LISA, the national 
register of education, all of which have been validated to have high quality data and 
completeness176, 177, 182, 185, 186 and have been operational during a long time. 
Since NREV has near complete coverage over the whole population of Sweden, selection bias 
should be minimal and allows us to study these patients in the routine clinical care as they are 
not highly selected as in a RCT. Thus, a major strength of the population-based register-based 
study is its high external validity and generalizability. 
Limitations in the data itself due to it being a national register is the poor detail on important 
confounding variables such as smoking and alcohol use. 
However, a large limitation in especially Paper II and Paper III studying short term outcomes 
and long-term outcomes after different extents of lymphadenectomy is selection bias. The 
decision to perform a certain lymphadenectomy lies under the responsible surgeon. Patient 
clinical functional level, comorbidities and stage of disease all are factors influencing survival 
and also might influence the surgeon’s decision on what extent of lymphadenectomy 
performed. Since the nature of the studies are register-based there is always an uncertainty that 
cannot be controlled as for an RCT 187. An issue of stage migration can also occur due to 
extended lymphadenectomy, but in paper III where we analyse long term survival, we have 
chosen to stage the disease according to clinical tumour stage instead of pathological tumour 
stage. However, an issue of different quality of preoperative work-up and classification across 
different regions still remain. In the studies we have tried to adjust for confounding factors 
between the different study groups of extent of lymphadenectomy with multivariable logistics 
regression and cox proportional hazard. The models include known factors that influence 
survival and are adjusted for. The database has a large study population and a long follow up 
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time thus we have the possibility to include several covariates and still have robustness in the 
model with a high number of events per variable. There might still be residual confounding and 
unknown important confounding factors might be missed. Therefore, the implications and 
conclusions drawn from Paper II and Paper III are more reserved. 
A strength of the register-based study design and its completeness is exemplified in Paper IV 
where we have the possibility to study all patients, especially patients that are not operated on. 
Since most RCT and also many retrospective case studies focus primarily on resected patients 
and study a single research question, far too little is known concerning the patients that are not 
operated on. In Paper IV we have the possibility to investigate how the resection rate influences 
survival in the entire population, and the variation of which across different geographical 
regions and years, which would be truly difficult to study with a different study design. 
 
5.3 ONCOLOGICAL THERAPY 
A substantial limitation in the current NREV is lack of details of oncological therapy. The last 
decades of improvement in gastric cancer care are in large due to the introduction of more 
oncological therapeutic alternatives. The pivotal MAGIC study 120 showed a survival benefit 
for perioperative chemotherapy versus surgery alone for gastroesophageal cancer. The 5-year 
survival rate was 36% versus 23% respectively. Along with the MAGIC study are also study 
comparing adjuvant chemoradiotherapy and more recent perioperative chemotherapy 119, 122, 
125, 126 all showing survival advantage. 
Most gastric cancer patients included in NREV during the study period 2006-2018 have been 
evaluated to receive oncological therapy. In our studies we have adjusted for the presence of 
oncological therapy in our multivariable analyses as this is important factor affecting survival. 
However, in our studies we have labelled it as preoperative chemotherapy. The different 
oncological studies mentioned previously have somewhat different regimens and either 
perioperative or adjuvant and some also have addition of radiotherapy. The NREV register has 
been updated regularly and there is from 2017 a prospective detailed robust section on 
oncological therapy. During the study periods in this thesis’ papers the detail of oncological 
therapy was not that specific, and we therefore only have reliable data on the preoperative part 
of perioperative chemotherapy, and unfortunately not the specific regimen nor if it was 
completed or fulfilled with reduced doses. Most patients have however received MAGIC 
regimen with ECF or modified version with EOX. Some have received treatment as part of the 
CRITICS trial 124 but very few have had addition of radiotherapy in the oncological treatment. 
Even though we do not have fully detailed data we still have valuable information in the 
register. In the MAGIC study as well as a Norwegian study 120, 130 show that only around half 
of the patients go on to receive the postoperative course of chemotherapy. And the CRITICS 
study 124 also show poor compliance to the postoperative treatment regimen and recommend 
further studies to optimize the preoperative part of treatment. The FLOT trial 126 which showed 
improved overall survival for the investigation arm (FLOT), also show that 60 % of patients 
  DISCUSSION | 51 
started the postoperative course and 46 % of patients finished all allocated cycles as compared 
to 52 % and 37 % respectively for the ECF/ECX treatment arm. Even in these RCT settings 
the postoperative compliance is low and in routine clinical care the estimated compliance of 
postoperative part of chemotherapy should be even lower. The use in our studies of 
preoperative chemotherapy as a confounding variable and adjusting for it should be fairly 
representative and not detrimental that we do not have complete detail of all cycles and the 
postoperative part. The survival effect of preoperative chemotherapy from the register data, 
Figure 11, are in similar numbers as the studies mentioned above comparing perioperative 
chemotherapy to surgery alone. 
 
5.4 LYMPHADENECTOMY 
The study of different extent of lymphadenectomy has been under great debate. Trials on 
surgical procedure or technique is always difficult and has been especially so in the studies on 
lymphadenectomy in gastric cancer. Our register studies show strength in its generalizability 
to everyday clinical practice but are lacking in detail. 
The first major concern in lymphadenectomy studies is that the terminology, definitions and 
procedure itself have changed over the years 20, 49, 64, 66, 184, 188, 189 thus making it difficult to 
compare different studies to each other. This is essential to interpreting the high postoperative 
morbidity and mortality in the Dutch RCT 72 where at the time pancreaticosplenectomy was 
routine in D2 for proximal cancers. The high postoperative morbidity and mortality was not 
seen in the later Italian trial 78 where routine pancreaticosplenectomy was not performed for 
D2. 
Another important factor is accuracy of the procedure. As described in the follow up analysis 
of lymphadenectomy in the Dutch trial 190 there was in the D1 group 80.5 % non-compliance 
and 25.8 % contamination. For the D2 group there was 81.6 % non-compliance and 28.7 % 
contamination. These factors warrant more careful interpretation of the register data. The time 
period for the register studies cover 2006-2017 and include clinical routine practice that follow 
and with some implementation delay the classification of lymphadenectomy of the JGCA 
treatment guidelines from English ver. 2 to ver. 4 66, 184, 188 where substantial changes were from 
ver. 2 to ver. 3. Our paper II uses the classification according to JGCA treatment guidelines 
ver. 3 which was the most recent one at the time. And Paper III uses the 4th English version. In 
our material we see non-compliance especially in station 1 and station 7 nodes for D1 
lymphadenectomy. This might be due to that the 2nd English version classified station 1 as tier 
2 node for lower (distal) gastric cancers and not necessary for D1, but in the 3rd and 4th version 
it is included to be mandatory for D1. Station 7 was classified as tier 2 node irrespective of 
location of cancer in the 2nd version but in the 3rd and 4th as mandatory for D1 
lymphadenectomy. This confusion together with the two first European RCT 74, 75 showing no 
improved results for D2 might have delayed the implementation of proper D2 
lymphadenectomy in clinical routine in Sweden. A consequence that we can see in our data is 
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that choosing to perform D1 on the basis that D2 was not superior at the time actually resulted 
in a large number of D0 lymphadenectomy in a lot of distal gastrectomy cases because of the 
omission of station 1 and station 7 nodes. This is the reason for why in paper II we have 
accepted D1 lymphadenectomy even if missing station 1 and 7 in distal gastrectomy and in 
paper III we have combined D0 and D1 patients together in the analysis.  
The registration of dissected lymphnode stations in NREV are typically performed by the 
responsible surgeon directly after surgery. Misclassification can occur, but data from paper II 
Figure 4, show that there is significantly increased amount of retrieved lymphnodes in the 
specimen for more extensive lymphadenectomy. 
For our register-based studies there are possibilities of patients classified as D2 to have not 
received the same adequate extent of lymphadenectomy. But this is also true for randomized 
trials as exemplified by the Dutch follow up study 190. This is the nature of studying outcomes 
of surgical intervention and surgical technique and in our best efforts to adjust, and account for 
those possible errors we feel that the results of our studies regarding D1+/D2 lymphadenectomy 
stands and that it is truly superior to D0/D1 lymphadenectomy when performed in routine 
clinical care that is offered to all patients in Sweden. 
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6 CONCLUSION 
Our studies show that the treatment for gastric cancer in Sweden varies across different regions 
of Sweden. There has been a substantial centralization over the last decade and treatment 
patterns of lymphadenectomy are changing. 
D2 lymphadenectomy during gastrectomy for cancer does not entail a high risk for 
postoperative pancreatic fistula in cases where direct pancreatic resection can be omitted. 
D1+/D2 lymphadenectomy during gastrectomy for cancer has over the last decades only been 
offered to a minority of patients 
D1+/D2 lymphadenectomy during gastrectomy for cancer can be performed safely with 
acceptable postoperative complication rate and low postoperative mortality in routine clinical 
healthcare 
D1+/D2 lymphadenectomy during gastrectomy for cancer is superior to D0/D1 
lymphadenectomy in regard to long term survival. 
The decision-making in gastric cancer treatment has room for standardisation and improvement 
in Sweden. 
The curative resection rate offered to patients varies greatly across different healthcare regions. 
A high resection rate is of survival benefit for the entire population with gastric cancer.  
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The results of this thesis leave many more questions unanswered. Future perspectives would 
be to analyse in more depth the possible reasons for geographical differences of treatment 
principles. Also, to study the effects on postoperative morbidity and mortality as well as long-
term survival the effects of the last decade’s centralization of care and more recent shift to more 
minimally invasive approach. 
 
More detailed studies on the effects of perioperative chemotherapy and its’ effect on surgical 
outcomes. Especially concerning perioperative chemotherapy and future emerging 
immunotherapy and its role in different molecular subtypes of gastric cancer. Larger databases 
and the emerging infrastructure with biobanking and next generation sequencing allows very 
interesting trials on the efficacy of oncological therapy in the molecular subtypes of gastric 
cancer. 
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Magsäckscancer är den femte vanligaste cancersjukdomen i världen och den cancerform som 
orsakar tredje flest dödsfall i världen. Historiskt sett har det varit den vanligaste cancerformen 
i världen men har senaste decennierna blivit mer ovanlig. I Sverige drabbas cirka 800 personer 
årligen. Prognosen för magsäckscancer är dyster med en 5 års överlevnad på endast ca 30 % 
av de som behandlas. Det finns dock geografiska skillnader och i östasiatiska länder som Japan 
och Sydkorea är magsäckscancer en mycket vanligare sjukdom och överlevnaden där också 
avsevärt bättre. Det finns skillnader i hur långt gången sjukdomen är när man upptäcker och 
behandlar den men det är inte den enda förklaringen till de bättre resultaten i de länderna. 
Möjligen beror det också på en kvalitetsskillnad i hur vi behandlar patienter med 
magsäckscancer. Kirurgi är grunden för botande behandling av magsäckscancer utan alltför 
stor spridning och syftar till att med marginal operera bort alla cancerceller i magsäcken och i 
de närliggande lymfkörtlarna. Kirurgin är dock behäftad med betydande risk för 
komplikationer. För att få bästa möjliga resultat vid kirurgi är det också viktigt att en stor andel 
av de lymfkörtlar som finns i närheten av tumören också opereras bort. Det brukar benämnas 
som omfattande lymfkörtelutrymning. För att studera behandlingen och vården av personer 
med magsäckscancer i Sverige har det inrättats ett nationellt kvalitetsregister. Det startades 
2006 och organiseras av Sveriges regionala cancercentrum och heter Nationella Registret för 
Esofagus och Ventrikelcancer (NREV). 
Våra studier baserade på NREV har visat på att optimal kirurgisk behandling med omfattande 
lymfkörtelutrymning för att kirurgisk avlägsna all cancervävnad sker i varierande grad i 
Sverige. Det finns regionala skillnader, men överlag över tid så är det fler och fler patienter 
som opereras med omfattande lymfkörtelutrymning. 
Våra resultat visar också att långtidsöverlevnaden för magsäckscancer förbättras om man 
opereras med omfattande lymfkörtelutrymning. Detta har tidigare varit känt i studier från 
Östasien men det har ej tidigare visats på europeiska studier på hela populationer. Här ser vi 
också att komplikationer efter operation för magsäckscancer inte förekommer avsevärt oftare 
vid omfattande lymfkörtelutrymning. 
En stor fördel med vårt nationella kvalitetsregister är att vi dessutom kan studera de personer 
med magsäckscancer som inte opereras. Mycket studier runtom i världen studerar endast de 
personer som går vidare till operation. Men majoriteten av de som får magsäckscancer kan inte 
opereras för sin sjukdom. Här har våra resultat visat att överlevnaden överlag är dålig om man 
inte opereras och att om man diagnosticeras i ett län med hög andel som opereras så ger det 
effekt och visar på att överlevnaden för hela gruppen förbättras. 
Sammanfattningsvis visar avhandlingen att för att ge hela populationen bästa behandling skall 
man sträva efter att erbjuda operation av magsäckscancer med syfte att bota och utföra 
operationen med omfattande lymfkörtelutrymning till så många patienter som möjligt. Det 
verkar finnas stora regionala skillnader i Sverige och mer arbete behöver göras för att så många 
som möjligt i Sverige skall erbjudas den mest optimala vården.  
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